Welcome to Paid Research Studies




  • Condition:   Non Hodgkin Lymphoma
    Intervention:   Drug: Tenalisib,
    Sponsor:   Rhizen Pharmaceuticals SA
    Recruiting

  • Condition:   Non-Hodgkin Lymphoma
    Intervention:   Biological: CD19-TriCAR-T/SILK
    Sponsor:   Timmune Biotech Inc.
    Recruiting

  • Condition:   Solid Tumors, Non-Hodgkin Lymphoma
    Intervention:   Drug: ADG106
    Sponsor:   Adagene Inc
    Recruiting

  • Condition:   Non-Hodgkin Lymphoma
    Interventions:   Drug: Copanlisib;   Drug: Venetoclax
    Sponsor:   Swiss Group for Clinical Cancer Research
    Recruiting

  • Condition:   Non-Hodgkin Lymphoma
    Intervention:   Biological: Tisagenlecleucel
    Sponsor:   Novartis Pharmaceuticals
    Recruiting

  • Condition:   Non Hodgkin Lymphoma
    Interventions:   Other: bone marrow puncture and venous blood samples;   Other: venous blood samples
    Sponsor:   Assiut University
    Not yet recruiting

  • Condition:   Non-hodgkin's Lymphoma
    Interventions:   Drug: Chiauranib;   Drug: Chidamide
    Sponsor:   Chipscreen Biosciences, Ltd.
    Not yet recruiting

  • Condition:   Non-Hodgkin Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: CAR-T Cells
    Sponsor:   Case Comprehensive Cancer Center
    Recruiting

  • Condition:   Non-Hodgkin Lymphoma
    Interventions:   Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy;   Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
    Sponsor:   Novartis Pharmaceuticals
    Recruiting

  • Condition:   Non Hodgkin Lymphoma
    Intervention:   Drug: Rituximab
    Sponsor:   Tahir Latif
    Recruiting

  • Condition:   Non-Hodgkin Lymphoma
    Intervention:   Diagnostic Test: 2-Deoxy-2-[18F]fluoro-D-glucose (FDG)
    Sponsor:   Abramson Cancer Center of the University of Pennsylvania
    Recruiting

  • Condition:   Non-hodgkin Lymphoma,B Cell
    Intervention:   Biological: TriCAR-T-CD19
    Sponsors:   Timmune Biotech Inc.;   Hunan Provincial People's Hospital
    Recruiting

  • Condition:   Non-Hodgkin Lymphoma
    Intervention:   Drug: Blinatumomab
    Sponsors:   Massachusetts General Hospital;   Amgen
    Recruiting

  • Condition:   Non-Hodgkin's Lymphoma
    Interventions:   Drug: Ibrutinib;   Drug: Obinutuzumab
    Sponsors:   Sidney Kimmel Cancer Center at Thomas Jefferson University;   Genentech, Inc.;   Pharmacyclics LLC.
    Recruiting

  • Condition:   Non-hodgkin Lymphoma,B Cell
    Intervention:   Biological: CD19-TriCAR-T
    Sponsor:   Timmune Biotech Inc.
    Recruiting

  • Condition:   Non Hodgkin Lymphoma
    Interventions:   Drug: acalabrutinib;   Drug: rituximab (IV);   Drug: Lenalidomide
    Sponsor:   Acerta Pharma BV
    Recruiting

  • Condition:   Non-Hodgkin's Lymphoma
    Interventions:   Drug: RO7082859;   Drug: Obinutuzumab;   Drug: Tocilizumab
    Sponsor:   Hoffmann-La Roche
    Recruiting

  • Conditions:   Relapsed Non-Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma
    Intervention:   Combination Product: CD19 CART
    Sponsors:   Chinese PLA General Hospital;   Shenzhen University;   Shenzhen University General Hospital
    Recruiting

  • Condition:   Aggressive Non-Hodgkin Lymphoma
    Interventions:   Drug: Pixantrone;   Other: Ifosfamide;   Other: Etoposide;   Other: Rituximab;   Procedure: Transplant
    Sponsor:   The Lymphoma Academic Research Organisation
    Recruiting

  • Conditions:   Solid Tumor;   Non-Hodgkin Lymphoma
    Intervention:   Drug: ADG106
    Sponsor:   Adagene (Suzhou) Limited
    Recruiting

  • Condition:   Non-hodgkin Lymphoma,B Cell
    Intervention:   Drug: Acalabrutinib
    Sponsor:   Seoul National University Hospital
    Recruiting

  • Condition:   Indolent Non-hodgkin Lymphoma
    Intervention:   Drug: Duvelisib
    Sponsor:   Verastem, Inc.
    Not yet recruiting

  • Conditions:   Relapsed Non Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma
    Interventions:   Drug: Rituximab;   Drug: Carboplatin;   Drug: Cytarabine Injection;   Drug: Dexamethasone;   Drug: Filgrastim 0.3 MG/ML
    Sponsor:   La Raza Medical Center
    Recruiting

  • Conditions:   Recurrent Non-Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma
    Interventions:   Radiation: External Beam Radiation Therapy;   Biological: Pembrolizumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   B-cell Non-Hodgkin Lymphoma
    Interventions:   Drug: Mosunetuzumab;   Drug: Polatuzumab vedotin;   Drug: Rituximab;   Drug: Bendamustine;   Drug: Obinutuzumab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone;   Drug: Tocilizumab
    Sponsor:   Hoffmann-La Roche
    Recruiting

  • Condition:   B-cell Non-Hodgkin Lymphoma
    Interventions:   Drug: Mosunetuzumab;   Drug: Polatuzumab Vedotin;   Drug: Rituxumab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone;   Drug: Tocilizumab
    Sponsor:   Hoffmann-La Roche
    Recruiting

  • Conditions:   Refractory Non Hodgkin Lymphoma;   Relapsed Non Hodgkin Lymphoma
    Interventions:   Biological: rituximab;   Biological: ibritumomab tiuxetan;   Biological: anti-thymocyte globulin;   Radiation: total nodal irradiation;   Procedure: peripheral blood stem cell transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil
    Sponsors:   University of California, Davis;   Spectrum Pharmaceuticals, Inc
    Recruiting

  • Condition:   Indolent B-Cell Non-Hodgkin Lymphoma
    Intervention:   Biological: BI1206
    Sponsor:   BioInvent International AB
    Recruiting

  • Condition:   T Cell Non-Hodgkin Lymphoma
    Intervention:   Other: High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin
    Sponsors:   Memorial Sloan Kettering Cancer Center;   University of Washington;   Weill Medical College of Cornell University;   H. Lee Moffitt Cancer Center and Research Institute
    Recruiting

  • Condition:   Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia
    Intervention:   Biological: Blinatumomab Expanded T-cells (BET)
    Sponsor:   A.O. Ospedale Papa Giovanni XXIII
    Recruiting

  • Condition:   Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
    Intervention:   Drug: ME-401
    Sponsor:   Kyowa Kirin Co., Ltd.
    Recruiting

  • Conditions:   Non-Hodgkin Lymphoma of Intestine;   Leukemia
    Intervention:   Biological: CD19-TriCAR-T/SILK
    Sponsors:   Timmune Biotech Inc.;   Hunan Provincial People's Hospital
    Recruiting

  • Conditions:   Non-Hodgkin Lymphoma;   Follicular Lymphoma
    Intervention:   Drug: Betalutin
    Sponsors:   Nordic Nanovector;   ICON Clinical Research
    Recruiting

  • Conditions:   Multiple Myeloma;   Non-Hodgkin's Lymphoma
    Interventions:   Drug: Meloxicam;   Drug: Filgrastim
    Sponsors:   Sherif S. Farag;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Metastatic Solid Tumors;   Relapsed/Refractory Non-Hodgkin Lymphoma
    Intervention:   Drug: MEN1309
    Sponsor:   Menarini Group
    Recruiting

  • Conditions:   B-cell Non-Hodgkin Lymphoma;   Aggressive
    Interventions:   Other: collected at pre-treatment tumor biopsy;   Other: Peripheral blood tests;   Device: PET/CT
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Mayo Clinic;   M.D. Anderson Cancer Center;   University of Pennsylvania;   University of Miami
    Recruiting

  • Conditions:   Non Hodgkin Lymphoma (NHL);   Diffuse Large B-cell Lymphoma (DLBCL)
    Interventions:   Drug: rituximab;   Drug: prednisone;   Behavioral: Geriatric Assessment
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Hodgkin Lymphoma;   Non-Hodgkin Lymphoma;   Hodgkin Disease
    Interventions:   Biological: Antigen-Escalation Stage;   Biological: Dose-Escalation Stage;   Biological: azacytidine and multiTAA T cells Stage;   Biological: Pediatric multiTAA T cells Stage
    Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   Texas Children's Hospital;   The Methodist Hospital System;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Non Hodgkin Lymphoma
    Intervention:   Drug: Abexinostat
    Sponsors:   Xynomic Pharmaceuticals, Inc.;   Chinese Academy of Medical Sciences
    Not yet recruiting

  • Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Non-Hodgkin's Lymphoma
    Intervention:   Drug: CG-806
    Sponsor:   Aptose Biosciences Inc.
    Recruiting

  • Condition:   B-Cell Non-Hodgkin Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Non-hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Relapsed Diffuse Large B-Cell Lymphoma
    Intervention:   Drug: MT-3724
    Sponsor:   Molecular Templates, Inc.
    Recruiting

  • Condition:   Diffuse Large B-cells Non-Hodgkin Lymphoma
    Intervention:   Drug: Rituximab-Dexamethasone-Lenalidomide
    Sponsor:   Fondazione Italiana Linfomi ONLUS
    Recruiting

  • Conditions:   Non-Hodgkin's Lymphoma;   Relapsed or Refractory B Cell Non-Hodgkin's Lymphoma;   Chronic Lymphoblastic Leukemia;   Peripheral T Cell Lymphoma
    Intervention:   Biological: Autologous γδT cells
    Sponsors:   Institute of Hematology & Blood Diseases Hospital;   Beijing GD Initiative Cell Therapy Technology Co.,Ltd.
    Not yet recruiting

  • Conditions:   Multiple Myeloma;   Non-Hodgkin Lymphoma;   B-Cell Lymphoma
    Interventions:   Drug: Tiragolumab;   Drug: Daratumumab;   Drug: Rituximab
    Sponsor:   Genentech, Inc.
    Recruiting

  • Conditions:   Follicular Lymphoma;   Marginal Zone Lymphoma;   Indolent Non-Hodgkin Lymphoma
    Interventions:   Biological: axicabtagene ciloleucel;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsor:   Kite, A Gilead Company
    Recruiting

  • Conditions:   Relapsed Non Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma
    Interventions:   Drug: Rituximab;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: MG4101(allogeneic Natural Killer cell);   Drug: Interleukin-2
    Sponsor:   Green Cross LabCell Corporation
    Recruiting

  • Conditions:   Non-hodgkin Lymphoma,B Cell;   Refractory Diffuse Large B-Cell Lymphoma;   Relapsed Diffuse Large B-Cell Lymphoma
    Intervention:   Drug: MT-3724
    Sponsor:   Molecular Templates, Inc.
    Recruiting

  • Conditions:   Relapse or Refractory Acute Myeloid Leukemia;   Relapse or Refractory Non-Hodgkin Lymphoma;   Relapse or Refractory Multiple Myeloma
    Intervention:   Drug: S65487
    Sponsors:   Institut de Recherches Internationales Servier;   ADIR, a Servier Group company
    Recruiting

  • Conditions:   Relapsed Non Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma;   CAR - T CD19/CD20/CD22/CD30
    Intervention:   Biological: CAR-T
    Sponsors:   The First Affiliated Hospital of Soochow University;   Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
    Recruiting

  • Conditions:   NHL;   DLBCL;   Non-hodgkin's Lymphoma;   Diffuse Large B Cell Lymphoma
    Interventions:   Drug: AZD9150;   Drug: Acalabrutinib;   Drug: AZD6738;   Drug: Hu5F9-G4;   Drug: Rituximab;   Drug: AZD5153
    Sponsors:   Acerta Pharma BV;   AstraZeneca
    Recruiting

  • Conditions:   Chronic Lymphocytic Leukemia;   Non-Hodgkin Lymphoma;   Untreated Chronic Lymphocytic Leukemia;   Vitamin D Deficiency
    Interventions:   Dietary Supplement: Cholecalciferol;   Other: Laboratory Biomarker Analysis
    Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Non-Hodgkin Lymphoma;   Follicular Lymphoma;   DLBCL;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma
    Intervention:   Drug: IGM-2323
    Sponsor:   IGM Biosciences, Inc.
    Recruiting

  • Conditions:   Non-Hodgkin's Lymphoma;   Multiple Myeloma
    Interventions:   Procedure: Hematopoietic Cell Transplantation;   Drug: Tbo-filgrastim
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma
    Interventions:   Biological: Yttrium Y 90 Basiliximab;   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Melphalan;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Non-Hodgkin Lymphoma;   Hodgkin Lymphoma
    Interventions:   Drug: Etoposide;   Drug: BCNU;   Drug: AraC;   Drug: Melphalan;   Procedure: Peripheral blood stem cell transplantation;   Biological: G-CSF;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Non-Hodgkin Lymphoma;   Diffuse Large B Cell Lymphoma;   Follicular Lymphoma;   Mantle-cell Lymphoma;   Primary Mediastinal B-cell Lymphoma
    Interventions:   Biological: JCAR017 (lisocabtagene maraleucel) single-dose schedule;   Biological: JCAR017 (lisocabtagene maraleucel) 2-dose schedule
    Sponsors:   Juno Therapeutics, Inc.;   Celgene
    Recruiting

  • Conditions:   Non-Hodgkin Lymphoma;   B-cell Acute Lymphoblastic Leukemia
    Interventions:   Genetic: PBCAR0191;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsor:   Precision BioSciences, Inc.
    Recruiting

  • Conditions:   Aggressive Non-Hodgkin Lymphoma;   Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma;   Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma;   Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Diffuse Large B-Cell Lymphoma;   High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements;   High Grade B-Cell Lymphoma, Not Otherwise Specified;   Indolent Non-Hodgkin Lymphoma;   Mediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma;   Transformed Non-Hodgkin Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Biological: Nivolumab;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsors:   Kami Maddocks;   National Cancer Institute (NCI);   Bristol-Myers Squibb
    Recruiting

  • Conditions:   Aggressive Non-Hodgkin Lymphoma;   Indolent Non-Hodgkin Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Recurrent T-Cell Non-Hodgkin Lymphoma;   Small Lymphocytic Lymphoma
    Interventions:   Procedure: Cryosurgery;   Biological: Dendritic Cell Therapy;   Biological: Pembrolizumab;   Biological: Pneumococcal 13-valent Conjugate Vaccine;   Other: Quality-of-Life Assessment
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Diffuse Large B-Cell Lymphoma;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Extranodal Marginal Zone Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Indolent Adult Non-Hodgkin Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Waldenstrom Macroglobulinemia;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Extranodal Marginal Zone Lymphoma;   Refractory Follicular Lymphoma;   Refractory Mantle Cell Lymphoma;   Stage III Non-Hodgkin Lymphoma;   Stage IV Non-Hodgkin Lymphoma;   Transformed Recurrent Non-Hodgkin Lymphoma
    Intervention:   Drug: Selinexor
    Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Refractory B-Cell Non-Hodgkin Lymphoma;   Relapsed B-cell Non-Hodgkin Lymphoma
    Intervention:   Biological: CAR-CD19 T Cells
    Sponsors:   Carsgen Therapeutics, Ltd.;   First Affiliated Hospital of Zhejiang University;   RenJi Hospital
    Not yet recruiting

  • Conditions:   Hematopoietic Cell Transplantation Recipient;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Marginal Zone Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Transformed Indolent Non-Hodgkin Lymphoma
    Interventions:   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Procedure: Hematopoietic Cell Transplantation;   Drug: Melphalan;   Drug: Venetoclax
    Sponsors:   Ohio State University Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Central Nervous System Lymphoma;   Gastric Mantle Cell Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Refractory Mantle Cell Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Splenic Mantle Cell Lymphoma
    Interventions:   Drug: Akt/ERK Inhibitor ONC201;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Relapsed/Refractory Follicular Non-Hodgkin Lymphoma
    Interventions:   Drug: BGB-3111;   Drug: obinutuzumab
    Sponsor:   BeiGene
    Recruiting

  • Conditions:   Metastatic Solid Tumors;   Hodgkin Lymphoma;   Non Hodgkin Lymphoma;   Non-small Cell Lung Cancer;   Melanoma;   Head and Neck Squamous Cell Carcinoma;   Gastric Adenocarcinoma;   Renal Cell Carcinoma;   Urothelial Carcinoma;   Esophageal Adenocarcinoma
    Intervention:   Drug: INBRX-105 - PDL1x41BB antibody
    Sponsor:   Inhibrx, Inc.
    Recruiting

  • Conditions:   Diffuse Large B-Cell Lymphoma;   B-cell Non-Hodgkin's Lymphoma
    Interventions:   Drug: Debio 1562;   Drug: Rituximab
    Sponsor:   Debiopharm International SA
    Recruiting

  • Conditions:   CD19 Positive;   Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mediastinal Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma;   Refractory Burkitt Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Mantle Cell Lymphoma;   Refractory Marginal Zone Lymphoma;   Refractory Mediastinal Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Small Lymphocytic Lymphoma
    Interventions:   Biological: Blinatumomab;   Drug: Lenalidomide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Non-Hodgkin's Lymphoma, Relapsed;   Chronic Lymphoid Leukemia in Relapse;   Non-Hodgkin's Lymphoma Refractory;   Chronic Lymphocytic Leukemia;   Lymphoma, Non-Hodgkin;   Leukemia, Lymphocytic, Chronic;   B-cell Chronic Lymphocytic Leukemia;   B-cell Non Hodgkin Lymphoma
    Interventions:   Genetic: PBCAR20A;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsor:   Precision BioSciences, Inc.
    Not yet recruiting

  • Conditions:   CD20 Positive;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Lymphoplasmacytic Lymphoma;   Refractory Mantle Cell Lymphoma;   Refractory Transformed Non-Hodgkin Lymphoma;   Recurrent Transformed B-cell Non-Hodgkin Lymphoma;   Recurrent Transformed Chronic Lymphocytic Leukemia;   Refractory Marginal Zone Lymphoma;   Refractory Transformed B-cell Non-Hodgkin Lymphoma;   Refractory Transformed Chronic Lymphocytic Leukemia
    Interventions:   Biological: Chimeric Antigen Receptor T-Cell Therapy;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Other: Laboratory Biomarker Analysis;   Procedure: Leukapheresis;   Drug: Fludarabine Phosphate
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   B-Cell Prolymphocytic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Lymphoplasmacytic Lymphoma;   Refractory Mantle Cell Lymphoma;   Refractory Marginal Zone Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Small Lymphocytic Lymphoma;   Richter Syndrome
    Interventions:   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Drug: Pevonedistat;   Other: Pharmacokinetic Study;   Other: Pharmacological Study
    Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Adult B Acute Lymphoblastic Leukemia;   BCL2 Gene Rearrangement;   BCL6 Gene Rearrangement;   CD19 Positive;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   MYC Gene Rearrangement;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Adult Acute Lymphoblastic Leukemia;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Recurrent Transformed Non-Hodgkin Lymphoma
    Interventions:   Biological: Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Other: Laboratory Biomarker Analysis;   Procedure: Leukapheresis;   Other: Pharmacological Study
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Non Hodgkin Lymphoma
    Intervention:   Drug: HMPL-523
    Sponsor:   Hutchison Medipharma Limited
    Recruiting

  • Condition:   Non Hodgkin Lymphoma
    Intervention:   Drug: R-CHOP + acalabrutinib
    Sponsor:   University Hospital Southampton NHS Foundation Trust
    Recruiting

  • Conditions:   Mantle Cell Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Indolent Adult Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Indolent Adult Non-Hodgkin Lymphoma
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Biological: Cord Blood-derived Expanded Allogeneic Natural Killer Cells;   Drug: Cytarabine;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Lenalidomide;   Drug: Melphalan;   Biological: Rituximab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Non-Hodgkin Lymphoma
    Intervention:  
    Sponsors:   Mayo Clinic;   Emory University;   University of Iowa;   M.D. Anderson Cancer Center;   Washington University School of Medicine;   University of Rochester;   Weill Medical College of Cornell University;   University of Miami
    Recruiting

  • Condition:   Lymphoma,Non-Hodgkin
    Interventions:   Drug: Copanlisib (BAY 80-6946);   Drug: Placebo;   Drug: Rituximab
    Sponsor:   Bayer
    Recruiting

  • Condition:   Non-Hodgkin Lymphoma
    Intervention:  
    Sponsor:   Alberta Health Services, Calgary
    Recruiting

  • Condition:   Lymphoma, Non-Hodgkin
    Interventions:   Drug: Copanlisib (BAY80-6946);   Drug: Placebo;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Bendamustine;   Drug: Prednisone
    Sponsor:   Bayer
    Recruiting

  • Condition:   Non-Hodgkin's Lymphoma
    Interventions:   Drug: Obinutuzumab;   Drug: Rituximab;   Drug: Polatuzumab Vedotin;   Drug: Venetoclax
    Sponsor:   Hoffmann-La Roche
    Recruiting

  • Conditions:   Chronic Lymphocytic Leukemia;   Richter Syndrome;   Diffuse Large B Cell Lymphoma;   Follicular Lymphoma;   Indolent Non-hodgkin Lymphoma;   Loss of Chromosome 17p;   Lymphoplasmacytic Lymphoma;   Marginal Zone Lymphoma;   TP53 Gene Mutation
    Interventions:   Drug: Copanlisib;   Biological: Nivolumab
    Sponsors:   OHSU Knight Cancer Institute;   Oregon Health and Science University;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   BCL2 Gene Rearrangement;   BCL6 Gene Rearrangement;   CD19 Positive;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   High-Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements;   MYC Gene Rearrangement;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
    Interventions:   Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014;   Drug: Cyclophosphamide;   Biological: Durvalumab;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsors:   Fred Hutchinson Cancer Research Center;   AstraZeneca;   Juno Therapeutics, Inc.;   MedImmune LLC;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Lymphoma, Non-Hodgkin;   Neoplasms
    Intervention:   Drug: CC-90011
    Sponsor:   Celgene
    Recruiting

  • Condition:   Relapsed Non Hodgkin Lymphoma
    Intervention:   Drug: Venetoclax
    Sponsor:   Nordic Lymphoma Group
    Recruiting

  • Conditions:   Lymphoma, Non-Hodgkin;   Lymphoma, Large B-Cell, Diffuse;   Indolent Lymphoma
    Interventions:   Drug: Hu5F9-G4;   Drug: Rituximab
    Sponsors:   Forty Seven, Inc.;   The Leukemia and Lymphoma Society
    Recruiting

  • Condition:   Aggressive Non-Hodgkin Lymphoma
    Interventions:   Drug: Prednisone;   Drug: Vinorelbine;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Rituximab
    Sponsor:   Fondazione Italiana Linfomi ONLUS
    Recruiting

  • Condition:   Indolent Non-hodgkin Lymphoma
    Interventions:   Drug: Obinutuzumab;   Drug: Bendamustine
    Sponsors:   Prof. Dr. Wolfgang Hiddemann;   Hoffmann-La Roche;   Mundipharma Research GmbH & Co KG
    Recruiting

  • Conditions:   Lymphoma, Non-Hodgkin;   Diffuse Large B Cell Lymphoma;   Follicular Lymphoma
    Intervention:   Biological: CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
    Sponsor:   Shanghai Ming Ju Biotechnology Co., Ltd.
    Recruiting

  • Conditions:   Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Acute Lymphocytic Leukemia
    Interventions:   Biological: CD19 CAR T Cells;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   Texas Children's Hospital;   The Methodist Hospital System
    Recruiting

  • Condition:   Lymphoma, Non-Hodgkin
    Interventions:   Drug: CC-99282;   Drug: rituximab
    Sponsor:   Celgene
    Not yet recruiting

  • Condition:   B-cell Non Hodgkin Lymphoma
    Intervention:   Biological: MB-CART2019.1
    Sponsors:   Miltenyi Biotec GmbH;   ICON plc
    Recruiting

  • Condition:   Lymphoma, Non-Hodgkin
    Interventions:   Drug: Standard of Care;   Genetic: JCAR017
    Sponsor:   Celgene
    Recruiting

  • Condition:   Follicular Non-Hodgkin's Lymphoma Refractory
    Intervention:   Drug: Idelalisib
    Sponsor:   Gilead Sciences
    Recruiting

  • Conditions:   Non-Hodgkin's Lymphoma;   Metastatic Breast Cancer;   Head and Neck Squamous Cell Carcinoma
    Interventions:   Drug: Pembrolizumab;   Drug: Flt3L;   Radiation: Radiation;   Drug: Poly ICLC
    Sponsors:   Icahn School of Medicine at Mount Sinai;   Merck Sharp & Dohme Corp.;   Celldex Therapeutics
    Recruiting

  • Condition:   Neoplasms
    Intervention:   Drug: GSK3326595.
    Sponsor:   GlaxoSmithKline
    Recruiting

  • Condition:   Lymphoma, Non-hodgkin
    Interventions:   Drug: TAK-981;   Drug: Rituximab
    Sponsor:   Millennium Pharmaceuticals, Inc.
    Not yet recruiting

  • Conditions:   Lymphoma, Non-Hodgkin;   Lymphoma, Follicular, Marginal Zone
    Intervention:   Drug: TAK-659
    Sponsor:   Millennium Pharmaceuticals, Inc.
    Recruiting

  • Conditions:   Lymphoma, Non-Hodgkin;   Lymphoma;   Lymphoma, B-Cell;   Lymphoma, Large B-Cell, Diffuse;   Neoplasms;   Neoplasms by Histologic Type;   Lymphoproliferative Disorders;   Lymphatic Diseases;   Immunoproliferative Disorders;   Immune System Disorder
    Intervention:   Biological: lisocabtagene maraleucel
    Sponsors:   Juno Therapeutics, Inc.;   Celgene Corporation
    Recruiting

  • Condition:   Gastrointestinal Lymphoma
    Intervention:   Diagnostic Test: Metagenomic shotgun sequencing
    Sponsor:   Ruijin Hospital
    Recruiting

  • Conditions:   Lymphoma, Non-Hodgkin;   Lymphoma, Large B-cell, Diffuse;   Lymphoma, Follicular
    Interventions:   Drug: TAK-659;   Drug: Venetoclax
    Sponsor:   Millennium Pharmaceuticals, Inc.
    Recruiting

  • Condition:   Lymphoma, Non-Hodgkin
    Interventions:   Drug: Ibrutinib;   Drug: Rituximab;   Drug: Ifosfamide;   Drug: Carboplatin;   Drug: Etoposide;   Drug: Vincristine;   Drug: Idarubicin;   Drug: Dexamethasone
    Sponsors:   Janssen Research & Development, LLC;   Pharmacyclics LLC.
    Recruiting

  • Conditions:   Lymphoma, Non-Hodgkin;   Lymphoma
    Interventions:   Drug: Carfilzomib;   Drug: Bendamustine;   Drug: Rituximab
    Sponsors:   University of California, San Francisco;   National Comprehensive Cancer Network
    Recruiting

  • Condition:   Mature B-cell Non-Hodgkin Lymphoma
    Interventions:   Drug: Rituximab window;   Drug: Additional doses of Rituximab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin hydrochloride;   Drug: Vindesine Sulfate;   Drug: Etoposide;   Drug: Ifosfamide;   Drug: Methotrexate;   Drug: Prednisolone;   Drug: Vincristine
    Sponsors:   University Hospital Muenster;   Deutsche Krebshilfe e.V., Bonn (Germany)
    Recruiting

  • Conditions:   Lymphoma, Non-Hodgkin;   Leukemia, Lymphocytic, Chronic, B-Cell
    Intervention:   Drug: MabThera
    Sponsor:   Hoffmann-La Roche
    Recruiting

  • Conditions:   Recurrent B-Cell Non-Hodgkin Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma
    Interventions:   Drug: Selicrelumab;   Drug: Atezolizumab
    Sponsors:   The Lymphoma Academic Research Organisation;   Roche Pharma AG
    Recruiting

  • Condition:   Waldenstrom Macroglobulinemia
    Intervention:   Drug: Umbralisib
    Sponsor:   TG Therapeutics, Inc.
    Recruiting

  • Condition:   Mature B-cell Non-Hodgkin Lymphoma
    Interventions:   Drug: Prednisone,Vincristine, Cyclophosphamide;   Drug: Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone;   Drug: Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone;   Drug: Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone;   Drug: Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone;   Drug: Rituximab
    Sponsors:   Children's Cancer Group, China;   Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, China;   Nanjing Children's Hospital;   West China Second University Hospital;   Xiangya Hospital of Central South University;   Qilu Hospital of Shandong University;   Children's Hospital Of Soochow University;   Tianjin Medical University Cancer Institute and Hospital
    Recruiting

  • Conditions:   Refractory Diffuse Large B Cell Lymphoma (DLBCL);   Relapsed Diffuse Large B-Cell Lymphoma;   Transformed Follicular Lymphoma (TFL);   Primary Mediastinal B-cell Lymphoma (PMBCL);   High Grade B-cell Lymphoma (HGBCL)
    Interventions:   Biological: Axicabtagene Ciloleucel;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsor:   Kite, A Gilead Company
    Recruiting

  • Condition:   Lymphoma, T-Cell, Peripheral
    Interventions:   Drug: MK-3475;   Drug: Copanlisib
    Sponsors:   Fox Chase Cancer Center;   Merck Sharp & Dohme Corp.
    Recruiting

  • Conditions:   NSCLC, Non Small Cell Lung Cancer;   RCC, Renal Cell Cancer;   Pancreatic Cancer;   Urothelial Cancer;   Head and Neck Cancer;   DLBCL, Diffused Large B Cell Lymphoma;   MSS, Microsatellite Stable Colon Cancer;   TNBC, Triple Negative Breast Cancer;   Melanoma
    Interventions:   Drug: NIR178;   Drug: PDR001
    Sponsor:   Novartis Pharmaceuticals
    Recruiting

  • Conditions:   Follicular Lymphoma;   Small Lymphocytic Lymphoma;   Marginal Zone Lymphoma;   Mucosal-Associated Lymphoid Tissue Lymphoma
    Interventions:   Dietary Supplement: Vitamin D;   Biological: Rituximab;   Other: Placebo
    Sponsors:   Jonathan Friedberg;   National Institutes of Health (NIH);   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
    Interventions:   Drug: zanubrutinib;   Drug: bendamustine;   Drug: rituximab
    Sponsor:   BeiGene
    Recruiting

  • Conditions:   Hematopoietic Cell Transplantation Recipient;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma;   Refractory T-Cell Non-Hodgkin Lymphoma
    Interventions:   Procedure: Allogeneic Bone Marrow Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Biological: Anti-Thymocyte Globulin;   Drug: Busulfan;   Drug: Clofarabine;   Drug: Gemcitabine Hydrochloride;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacological Study;   Biological: Rituximab;   Drug: Tacrolimus
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   B-cell Non Hodgkin Lymphoma;   Pre B-Cell Acute Lymphoblastic Leukaemia
    Interventions:   Drug: Blinatumomab;   Drug: Dexamethasone
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Amgen
    Recruiting

  • Conditions:   T Cell Non-Hodgkin Lymphoma;   Peripheral T-Cell Lymphoma, Not Otherwise Specified;   Angioimmunoblastic T-cell Lymphoma;   Anaplastic Large Cell Lymphoma
    Intervention:   Biological: AUTO4
    Sponsor:   Autolus Limited
    Recruiting

  • Conditions:   Lymphocytic Leukemia, Chronic;   Lymphoma, Non Hodgkin
    Interventions:   Drug: BTCT4465A (Mosunetuzumab) IV;   Drug: Atezolizumab;   Drug: BTCT4465A (Mosunetuzumab) SC
    Sponsor:   Genentech, Inc.
    Recruiting

  • Conditions:   Diffuse Large B-Cell Lymphoma;   Follicular Lymphoma;   Marginal Zone Lymphoma;   Mantle Cell Lymphoma
    Interventions:   Drug: TGR-1202 + Ublituximab;   Drug: TGR-1202;   Drug: TGR-1202 + Ublituximab + Bendamustine
    Sponsor:   TG Therapeutics, Inc.
    Recruiting

  • Conditions:   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma
    Interventions:   Drug: Bendamustine;   Drug: Carmustine;   Drug: Etoposide;   Drug: Melphalan;   Drug: Cytarabine;   Drug: Alemtuzumab;   Biological: Autologous Stem Cell Transplantation;   Biological: Allogeneic Stem Cell Transplantation;   Drug: Rituximab
    Sponsor:   Weill Medical College of Cornell University
    Recruiting

  • Conditions:   Lymphoblastic Leukemia, Acute, Childhood;   Lymphoblastic Lymphoma;   Peripheral T-cell Lymphoma
    Interventions:   Drug: Temsirolimus;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Methotrexate;   Drug: Hydrocortisone;   Drug: Cytarabine
    Sponsors:   Therapeutic Advances in Childhood Leukemia Consortium;   Pfizer
    Recruiting

  • Conditions:   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Nodal Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Recurrent Splenic Marginal Zone Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Refractory Follicular Lymphoma;   Refractory Lymphoplasmacytic Lymphoma;   Refractory Nodal Marginal Zone Lymphoma;   Refractory Small Lymphocytic Lymphoma;   Refractory Splenic Marginal Zone Lymphoma;   Richter Syndrome;   Waldenstrom Macroglobulinemia
    Interventions:   Drug: Ibrutinib;   Drug: Idelalisib;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Prolymphocytic Leukemia;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia
    Interventions:   Drug: Selinexor;   Drug: Ibrutinib;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
    Sponsors:   Jennifer Woyach;   National Cancer Institute (NCI);   Karyopharm Therapeutics Inc
    Recruiting

  • Conditions:   Chronic Lymphocytic Leukemia;   Non Hodgkin Lymphoma
    Intervention:   Drug: APG-2575
    Sponsor:   Ascentage Pharma Group Inc.
    Recruiting

  • Conditions:   Diffuse Large B-Cell Lymphoma (DLBCL);   Primary Mediastinal Large B-cell Lymphoma;   Burkitt Lymphoma;   Anaplastic Large-Cell Lymphoma;   Gray Zone Lymphoma
    Interventions:   Drug: EPOCH;   Biological: Rituximab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Non Hodgkin Lymphoma;   Breast Cancer
    Interventions:   Device: On-body injector;   Device: Pre-filled syringe
    Sponsors:   iOMEDICO AG;   Amgen
    Recruiting

  • Conditions:   Hodgkin Lymphoma;   Non-hodgkin Lymphoma
    Intervention:   Biological: AB-205
    Sponsors:   Angiocrine Bioscience;   California Institute for Regenerative Medicine (CIRM)
    Recruiting

  • Conditions:   Non-hodgkin Lymphoma;   Acute Lymphoblastic Leukemia
    Interventions:   Biological: CD19.CAR-multiVST for Group A;   Biological: CD19.CAR-multiVST for Group B
    Sponsors:   Baylor College of Medicine;   Texas Children's Hospital;   The Methodist Hospital System;   Center for Cell and Gene Therapy, Baylor College of Medicine
    Not yet recruiting

  • Conditions:   Hodgkin's Lymphoma;   Non-Hodgkin Lymphoma
    Interventions:   Genetic: CAR T Cells;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsors:   Baylor College of Medicine;   The Methodist Hospital System;   Texas Children's Hospital
    Recruiting

  • Conditions:   Lymphoma, Malignant;   Non-hodgkin Lymphoma
    Intervention:   Drug: DS-3201b
    Sponsors:   Daiichi Sankyo Co., Ltd.;   Daiichi Sankyo, Inc.
    Recruiting

  • Conditions:   Non Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia
    Interventions:   Drug: TG-1701;   Drug: Umbralisib;   Biological: Ublituximab
    Sponsor:   TG Therapeutics, Inc.
    Recruiting

  • Conditions:   Mycosis Fungoides;   Non-Hodgkin's Lymphoma
    Intervention:  
    Sponsor:   Stanford University
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Non-Hodgkin's Lymphoma
    Intervention:   Biological: CLIC-1901
    Sponsor:   Ottawa Hospital Research Institute
    Not yet recruiting

  • Conditions:   Non-Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia
    Intervention:   Drug: REGN1979 multiple dose levels
    Sponsor:   Regeneron Pharmaceuticals
    Recruiting

  • Conditions:   Mantle Cell Lymphoma;   Non-hodgkin Lymphoma;   Non Hodgkin Lymphoma
    Interventions:   Drug: Bendamustine;   Drug: Obinutuzumab
    Sponsors:   University of Wisconsin, Madison;   Genentech, Inc.;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Classical Hodgkin Lymphoma;   B-cell Non Hodgkin Lymphoma
    Intervention:   Drug: TG-1501
    Sponsor:   TG Therapeutics, Inc.
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia (ALL);   Non Hodgkin Lymphoma (NHL)
    Intervention:   Biological: CD19-UCART
    Sponsors:   Shanghai Bioray Laboratory Inc.;   The First Affiliated Hospital of Zhengzhou University;   Second Xiangya Hospital of Central South University;   Shanghai 10th People's Hospital
    Recruiting

  • Conditions:   Diffuse Large B Cell Lymphoma;   Relapsed Non Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma
    Intervention:   Drug: azacitidine plus R-GDP
    Sponsor:   Seoul National University Hospital
    Not yet recruiting

  • Conditions:   Follicular Lymphoma;   Non-Hodgkin's Lymphoma Follicular;   Non-Hodgkin's Lymphoma, Adult High Grade
    Interventions:   Drug: Induction Venetoclax;   Drug: Maintenance Venetoclax
    Sponsors:   PrECOG, LLC.;   Genentech, Inc.
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   FGFR1 Gene Mutation;   FGFR2 Gene Mutation;   FGFR3 Gene Mutation;   FGFR4 Gene Mutation;   Histiocytosis;   Low Grade Glioma;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Wilms Tumor
    Interventions:   Drug: Erdafitinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Hodgkin Lymphoma;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   EZH2 Gain of Function;   EZH2 Gene Mutation;   Histiocytosis;   Loss of BRG1 Protein Expression;   Loss of INI 1 Protein Expression;   Low Grade Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Hodgkin Lymphoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Glioma;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Hodgkin Lymphoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Glioma;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Soft Tissue Sarcoma;   Rhabdoid Tumor;   SMARCA4 Gene Inactivation;   SMARCB1 Gene Inactivation;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Wilms Tumor
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Tazemetostat
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   BRAF NP_004324.2:p.V600X;   Ependymoma;   Ewing Sarcoma;   Hepatoblastoma;   Langerhans Cell Histiocytosis;   Malignant Germ Cell Tumor;   Malignant Glioma;   Osteosarcoma;   Peripheral Primitive Neuroectodermal Tumor;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Rhabdomyosarcoma;   Soft Tissue Sarcoma;   Wilms Tumor
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Vemurafenib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Stage III Osteosarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Osteosarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7;   TSC1 Gene Mutation;   TSC2 Gene Mutation;   Wilms Tumor
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Samotolisib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Deleterious ATM Gene Mutation;   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Deleterious RAD51C Gene Mutation;   Deleterious RAD51D Gene Mutation;   Histiocytosis;   Low Grade Glioma;   Malignant Glioma;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Childhood Malignant Germ Cell Tumor;   Refractory Ependymoma;   Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Glioma;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Rhabdoid Tumor;   Wilms Tumor
    Intervention:   Drug: Olaparib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   ALK Fusion Protein Expression;   ALK Gene Mutation;   ALK Gene Translocation;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Histiocytosis;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   ROS1 Fusion Positive;   ROS1 Gene Mutation;   ROS1 Gene Translocation
    Interventions:   Drug: Ensartinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Childhood Langerhans Cell Histiocytosis;   Histiocytic Sarcoma;   Juvenile Xanthogranuloma;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Refractory Central Nervous System Neoplasm;   Refractory Childhood Malignant Germ Cell Tumor;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Rhabdoid Tumor;   Stage III Osteosarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Osteosarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7;   Wilms Tumor
    Interventions:   Procedure: Biopsy;   Procedure: Biospecimen Collection;   Drug: Ensartinib;   Drug: Erdafitinib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Procedure: Mutation Carrier Screening;   Drug: Olaparib;   Drug: Palbociclib;   Other: Pharmacological Study;   Drug: Samotolisib;   Drug: Selumetinib Sulfate;   Drug: Tazemetostat;   Drug: Ulixertinib;   Drug: Vemurafenib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Recurrent Anaplastic Large Cell Lymphoma;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Classic Hodgkin Lymphoma;   Recurrent Mycosis Fungoides;   Recurrent Peripheral T-Cell Lymphoma;   Refractory Anaplastic Large Cell Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Classic Hodgkin Lymphoma;   Refractory Mycosis Fungoides;   Refractory Peripheral T-Cell Lymphoma;   TNFRSF8 Positive
    Interventions:   Biological: Anti-CD30/CD16A Monoclonal Antibody AFM13;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Fludarabine Phosphate;   Biological: Genetically Engineered Lymphocyte Therapy
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Non Hodgkin Lymphoma;   Follicular Lymphoma;   Indolent Lymphoma;   B-cell Lymphoma;   Transformed Lymphoma;   Marginal Zone Lymphoma;   Waldenstrom Macroglobulinemia;   Small Lymphocytic Lymphoma;   Lymphoplasmacytic Lymphoma
    Intervention:   Drug: Zydelig
    Sponsors:   University of Maryland, College Park;   Gilead Sciences;   University of Miami Sylvester Comprehensive Cancer Center
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   NTRK1 Fusion Positive;   NTRK2 Fusion Positive;   NTRK3 Fusion Positive;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Glioma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Recurrent Rhabdoid Tumor;   Refractory Central Nervous System Neoplasm;   Refractory Childhood Malignant Germ Cell Tumor;   Refractory Ependymoma;   Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Glioma;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Wilms Tumor
    Interventions:   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   RB1 Positive;   Recurrent Childhood Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Kidney Wilms Tumor;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Glioma;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Ependymoma;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Glioma;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Palbociclib;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Follicular Lymphoma (FL/Indolent NHL);   Aggressive NHL (a NHL);   Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL);   T-cell Lymphoma (PTCL and CTCL);   B-cell Non Hodgkin Lymphoma (NHL)
    Intervention:   Drug: Cerdulatinib (PRT062070)
    Sponsor:   Portola Pharmaceuticals
    Recruiting

  • Conditions:   B-Cell Non-Hodgkin Lymphoma;   Grade 1 Follicular Lymphoma;   Grade 2 Follicular Lymphoma;   Grade 3a Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   Small Lymphocytic Lymphoma
    Interventions:   Biological: Anti-OX40 Antibody BMS 986178;   Other: Laboratory Biomarker Analysis;   Radiation: Radiation Therapy;   Drug: TLR9 Agonist SD-101
    Sponsors:   Ronald Levy;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Chronic Lymphocytic Leukemia (CLL);   Small Lymphocytic Lymphoma (SLL);   Follicular Lymphoma (FL);   Marginal Zone B Cell Lymphoma;   Diffuse Large B-cell Lymphoma (DLBCL);   High Grade Non-Hodgkin's Lymphoma;   Mantle Cell Lymphoma (MCL)
    Interventions:   Drug: ME-401;   Drug: Rituximab;   Drug: Zanubrutinib
    Sponsor:   MEI Pharma, Inc.
    Recruiting

  • Conditions:   B-cell Malignancy;   Non-Hodgkin Lymphoma;   B-cell Lymphoma
    Intervention:   Biological: CTX110
    Sponsor:   CRISPR Therapeutics AG
    Recruiting

  • Conditions:   T-cell Acute Lymphoblastic Lymphoma;   T-non-Hodgkin Lymphoma;   T-cell Acute Lymphoblastic Leukemia
    Interventions:   Genetic: CD5.CAR/28zeta CAR T cells;   Drug: Fludarabine;   Drug: Cytoxan
    Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   The Methodist Hospital System;   Texas Children's Hospital
    Recruiting

  • Conditions:   T-cell Acute Lymphoblastic Leukemia;   T-cell Acute Lymphoblastic Lymphoma;   T-non-Hodgkin Lymphoma
    Interventions:   Genetic: CD7.CAR/28zeta CAR T cells;   Drug: Fludarabine;   Drug: Cytoxan
    Sponsors:   Baylor College of Medicine;   The Methodist Hospital System;   Texas Children's Hospital;   Center for Cell and Gene Therapy, Baylor College of Medicine
    Not yet recruiting

  • Conditions:   Non Hodgkin Lymphoma;   Non Small Cell Lung Cancer;   Glioma
    Intervention:  
    Sponsor:   Assistance Publique - Hôpitaux de Paris
    Not yet recruiting

  • Conditions:   Acute Myeloid Leukemia;   Non-Hodgkin's Lymphoma;   Diffuse Large B-cell Lymphoma
    Interventions:   Drug: Venetoclax;   Drug: AMG 176
    Sponsors:   AbbVie;   Genentech, Inc.;   Amgen
    Recruiting

  • Condition:   Lymphoma, Non-Hodgkin
    Intervention:   Drug: JCAR017
    Sponsor:   Celgene
    Recruiting

  • Conditions:   Multiple Myeloma;   Non-Hodgkin Lymphoma;   Diffuse Large B Cell Lymphoma;   Mantle-Cell Lymphoma;   Follicular Lymphoma;   Indolent B Cell Lymphoma;   Primary Mediastinal Lymphoma;   Lymphoplasmacytic Lymphoma
    Intervention:   Biological: Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Non Hodgkin Lymphoma;   Follicular Lymphoma;   Relapsed Follicular Lymphoma
    Intervention:   Drug: Betalutin
    Sponsors:   Nordic Nanovector;   ICON Clinical Research
    Recruiting

  • Conditions:   Hodgkin Lymphoma;   Non-hodgkin Lymphoma;   Lymphoma
    Interventions:   Other: Physical Activity Intervention (PAI);   Other: Healthy Living Control
    Sponsor:   Virginia Commonwealth University
    Recruiting

  • Conditions:   Follicular Lymphoma;   Non-Hodgkin's Lymphoma;   NHL
    Interventions:   Biological: Rituximab;   Drug: Copanlisib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Non-Hodgkin's Lymphoma;   B-Cell ALL;   B-Cell CLL
    Interventions:   Genetic: CD19.CAR-CD28Z T Cells - dose escalation 2;   Genetic: CD19.CAR-CD28Z T Cells - dose escalation 1
    Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   Texas Children's Hospital;   The Methodist Hospital System
    Recruiting

  • Conditions:   Mediastinal Lymphoma;   Hodgkin Lymphoma;   Non Hodgkin Lymphoma
    Intervention:   Radiation: Standard treatment protocol with combined chemoradiation
    Sponsor:   Chang Gung Memorial Hospital
    Recruiting

  • Conditions:   Non-Hodgkin's Lymphoma;   Myeloma;   Active Solid Malignancy
    Intervention:   Drug: PET Imaging using 124 IPUH71
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Samus Therapeutics
    Recruiting

  • Conditions:   Non Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Multiple Myeloma
    Intervention:  
    Sponsors:   Centre Hospitalier Intercommunal Creteil;   ANSES
    Recruiting

  • Conditions:   Diffuse Large B-cell Lymphoma;   Acute Myeloid Leukemia;   Non-Hodgkin's Lymphoma
    Interventions:   Drug: Venetoclax;   Drug: Selinexor
    Sponsors:   Michael Byrne;   Karyopharm Therapeutics Inc;   AbbVie
    Recruiting

  • Conditions:   Non-Hodgkin's Lymphoma;   Hodgkin Lymphoma;   Multiple Myeloma
    Interventions:   Biological: Nivolumab;   Biological: Ipilimumab;   Biological: Lirilumab;   Biological: Daratumumab;   Drug: Pomalidomide;   Drug: Dexamethasone
    Sponsors:   Bristol-Myers Squibb;   Janssen, LP
    Recruiting

  • Conditions:   Relapsed Non Hodgkin Lymphoma;   Relapsed Adult ALL;   Relapsed Pediatric ALL
    Intervention:   Biological: autologous CD19-directed chimeric antigen receptor (CAR) T-cells
    Sponsors:   University of Alberta;   Alberta Cancer Foundation;   Canadian Cancer Trials Group
    Not yet recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Lymphoblastic Lymphoma;   Diffuse Large B-cell Lymphoma;   Burkitt Lymphoma/Leukemia
    Interventions:   Drug: Clofarabine;   Drug: Mitoxantrone
    Sponsor:   New York Medical College
    Recruiting

  • Conditions:   Leukemia, Lymphocytic, Chronic, B-Cell;   Lymphoma, Non-Hodgkin
    Intervention:   Drug: JNJ-67856633
    Sponsor:   Janssen Research & Development, LLC
    Recruiting

  • Conditions:   Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   B-cell Lymphoma Refractory;   B-cell Lymphoma Recurrent
    Intervention:   Biological: MB-CART20.1
    Sponsor:   Miltenyi Biotec GmbH
    Recruiting

  • Conditions:   Lymphoma, Large B-Cell, Diffuse;   Stage III Follicular Lymphoma
    Interventions:   Drug: Metformin;   Drug: Placebos
    Sponsor:   Ruijin Hospital
    Recruiting

  • Conditions:   B-cell Non-Hodgkins Lymphoma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
    Intervention:   Biological: XmAb13676
    Sponsors:   Xencor, Inc.;   Chiltern International Inc.
    Recruiting

  • Conditions:   B-ALL;   B-cell Non Hodgkin Lymphoma;   DLBCL
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: CD22 CAR
    Sponsor:   Stanford University
    Recruiting

  • Conditions:   Relapsed, Diffuse Large B-cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
    Intervention:   Drug: Betalutin
    Sponsor:   Nordic Nanovector
    Recruiting

  • Conditions:   B-Cell Non-Hodgkin Lymphoma;   Follicular Lymphoma;   Indolent Non-Hodgkin Lymphoma;   Marginal Zone Lymphoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Chronic Lymphocytic Leukemia;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Small Lymphocytic Lymphoma;   Waldenstrom Macroglobulinemia
    Interventions:   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis;   Biological: Rituximab
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Adult Burkitt Lymphoma;   B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma;   Diffuse Large B-Cell Lymphoma;   MYC Gene Mutation;   Plasmablastic Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Prednisone;   Biological: Rituximab;   Drug: Therapeutic Hydrocortisone;   Drug: Vincristine Sulfate
    Sponsors:   Northwestern University;   National Cancer Institute (NCI);   Millennium Pharmaceuticals, Inc.
    Recruiting

  • Conditions:   Anemia;   B-Cell Prolymphocytic Leukemia;   Fatigue;   Fever;   Grade 1 Follicular Lymphoma;   Grade 2 Follicular Lymphoma;   Grade 3a Follicular Lymphoma;   Hairy Cell Leukemia;   Lymphadenopathy;   Lymphocytosis;   Lymphoplasmacytic Lymphoma;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   Night Sweats;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Small Lymphocytic Lymphoma;   Richter Syndrome;   Splenomegaly;   Thrombocytopenia;   Weight Loss
    Interventions:   Drug: Entospletinib;   Other: Laboratory Biomarker Analysis;   Biological: Obinutuzumab;   Other: Pharmacological Study
    Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Lymphoma, AIDS-related;   Lymphoma, Large B-Cell, Diffuse
    Interventions:   Biological: Rituximab;   Biological: filgrastim;   Drug: EPOCH
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Chronic Lymphocytic Leukemia;   Waldenstrom Macroglobulinemia;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   B-cell Lymphoma;   Small Lymphocytic Lymphoma
    Intervention:   Drug: LOXO-305
    Sponsor:   Loxo Oncology, Inc.
    Recruiting

  • Conditions:   Central Nervous System B-Cell Non-Hodgkin Lymphoma;   Recurrent Central Nervous System Lymphoma;   Refractory Central Nervous System Lymphoma
    Interventions:   Drug: Ibrutinib;   Biological: Nivolumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Post-transplant Lymphoproliferative Disorder;   B-Cell Prolymphocytic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma;   B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma
    Interventions:   Drug: cyclophosphamide;   Other: laboratory biomarker analysis;   Drug: Bendamustine Hydrochloride;   Drug: Etoposide;   Drug: Fludarabine Phosphate;   Biological: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Chronic Lymphocytic Leukemia (CLL);   Small Lymphocytic Lymphoma (SLL);   B-Cell Non-Hodgkin Lymphomas(NHL)
    Intervention:   Drug: SHC014748M
    Sponsor:   Nanjing Sanhome Pharmaceutical, Co., Ltd.
    Recruiting

  • Conditions:   Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma;   Recurrent Mycosis Fungoides;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Refractory Mycosis Fungoides
    Interventions:   Biological: Pembrolizumab;   Drug: Pralatrexate
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Diffuse Large B Cell Lymphoma;   High-grade B-cell Lymphoma;   Transformed Lymphoma;   Primary Mediastinal Large B Cell Lymphoma
    Intervention:   Biological: BZ019
    Sponsors:   Institute of Hematology & Blood Diseases Hospital;   Shanghai Cell Therapy Engineering Technology Research Center Group Co., Ltd.
    Recruiting

  • Conditions:   Non-Hodgkin's Lymphoma;   Hodgkin's Disease;   Leukemia, Lymphocytic, Chronic;   Lymphoproliferative Disorders
    Intervention:  
    Sponsor:   Dana-Farber Cancer Institute
    Recruiting

  • Conditions:   Lymphoma;   Lymphoma, Non-Hodgkin;   Immune System Diseases;   Immunoproliferative Disorders;   Lymphatic Diseases;   Lymphoproliferative Disorders;   Neoplasms;   Cutaneous Lymphoma;   Cutaneous Anaplastic Large Cell Lymphoma;   Mycosis Fungoides;   Sezary Syndrome;   Lymphomatoid Papulosis
    Interventions:   Biological: ATLCAR.CD30.CCR4 cells;   Biological: ALTCAR.CD30 cells;   Drug: Bendamustine;   Drug: Fludarabine
    Sponsor:   UNC Lineberger Comprehensive Cancer Center
    Recruiting

  • Condition:   CD20 Positive B Cell NHL
    Interventions:   Drug: 304 injection;   Drug: rituximab injection
    Sponsor:   Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
    Recruiting

  • Conditions:   Hodgkin Lymphoma;   Diffuse Large B Cell Lymphoma;   Peripheral T-Cell Lymphoma
    Intervention:   Drug: Pembrolizumab
    Sponsors:   Dana-Farber Cancer Institute;   Merck Sharp & Dohme Corp.
    Recruiting

  • Conditions:   Hepatitis B;   Lymphoma;   Non-Hodgkin
    Interventions:   Drug: Tenofovir disoproxil;   Drug: Placebo Oral Tablet
    Sponsor:   University Health Network, Toronto
    Recruiting

  • Conditions:   Lymphoma;   Lymphoma, Non-Hodgkin;   Immune System Diseases;   Immunoproliferative Disorders;   Lymphatic Diseases;   Lymphoproliferative Disorders;   Neoplasms;   Neoplasms by Histologic Type
    Intervention:   Biological: ATLCAR.CD30 cells
    Sponsor:   UNC Lineberger Comprehensive Cancer Center
    Recruiting

  • Conditions:   Hodgkin's Disease;   Non-Hodgkin's Lymphoma;   Lymphoproliferative Disease;   Lymphoma
    Interventions:   Biological: LMP, BARF1 & EBNA1 specific CTLs: A;   Biological: LMP, BARF1 & EBNA1 specific CTLs : B
    Sponsors:   Baylor College of Medicine;   Texas Children's Hospital;   The Methodist Hospital System;   Center for Cell and Gene Therapy, Baylor College of Medicine;   National Institutes of Health (NIH);   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   NHL;   Solid Tumors
    Interventions:   Drug: KPT-9274;   Drug: KPT-9274 & Niacin ER
    Sponsor:   Karyopharm Therapeutics Inc
    Recruiting

  • Conditions:   B-Lymphoid Malignancies;   Acute Lymphocytic Leukemia;   Chronic Lymphocytic Leukemia;   Non-hodgkin Lymphoma
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Mesna;   Biological: iC9/CAR.19/IL15-Transduced CB-NK Cells;   Drug: AP1903
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Lymphoma, Non-Hodgkin;   Lymphoma, Follicular;   Lymphoma, Mantle-Cell;   Lymphoma, Small-Cell;   Waldenstrom Macroglobulinemia;   Lymphoma, B-Cell, Marginal Zone
    Interventions:   Drug: Rituximab;   Drug: Bendamustine;   Drug: Vincristine sulfate liposome injection
    Sponsors:   Adam Olszewski;   Spectrum Pharmaceuticals, Inc;   Rhode Island Hospital;   The Miriam Hospital
    Recruiting

  • Conditions:   Diffuse Large B-Cell Lymphoma;   Non Hodgkin's Lymphoma;   DLBCL;   NHL
    Interventions:   Drug: DA-EPOCH;   Biological: Rituximab;   Drug: CHOP;   Drug: Acalabrutinib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Lymphoma;   Non-Hodgkin Lymphoma;   Diffuse Large B-Cell Lymphoma;   Burkitt Lymphoma
    Interventions:   Drug: Venetoclax;   Drug: Ibrutinib;   Drug: Prednisone;   Drug: Obinutuzumab;   Drug: Revlimid (lenalidomide)
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Hodgkin Disease;   Non-Hodgkin Lymphoma;   Severe Chronic Active Epstein Barr Virus;   T/NK-lymphoproliferative Disease
    Interventions:   Biological: MABEL CTLs;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   Texas Children's Hospital;   The Methodist Hospital System
    Recruiting

  • Conditions:   Haematological Malignancy;   Acute Myeloid Leukemia;   Non Hodgkin Lymphoma;   Multiple Myeloma
    Intervention:   Drug: CCS1477
    Sponsor:   CellCentric Ltd.
    Recruiting

  • Conditions:   Neoplasms;   Solid Tumor, Adult;   Non-Hodgkin Lymphoma;   Myelodysplastic Syndromes
    Intervention:   Drug: JNJ-64619178
    Sponsor:   Janssen Research & Development, LLC
    Recruiting

  • Conditions:   Leukemia;   Multiple Myeloma;   Myelodysplastic Syndrome;   Non-Hodgkin's Lymphoma
    Interventions:   Biological: Palifermin;   Biological: Lupron;   Procedure: peripheral blood stem cell transplantation;   Radiation: Total-Body Irradiation (TBI);   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Degarelix
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Swedish Orphan Biovitrum
    Recruiting

  • Conditions:   Diffuse Large B-Cell Lymphoma;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma
    Interventions:   Biological: Mogamulizumab;   Biological: Pembrolizumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Lymphomatoid Granulomatosis;   Granulomatosis, Lymphomatoid;   Non-Hodgkins Lymphoma;   Lymphoproliferative Disorder
    Interventions:   Biological: Interferon;   Drug: Rituxan and EPOCH
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   CD30-Positive Neoplastic Cells Present;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma
    Interventions:   Drug: Brentuximab Vedotin;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myelogenous Leukemia (AML);   Acute Lymphoblastic Leukemia (ALL);   Non Hodgkin Lymphoma (NHL);   Hodgkin Lymphoma, Adult
    Intervention:   Other: non intervational
    Sponsor:   Cellect Biotechnology
    Recruiting

  • Conditions:   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory B-Cell Small Lymphocytic Lymphoma;   Relapsed Adult ALL;   Relapsed CLL;   Relapsed Non Hodgkin Lymphoma
    Interventions:   Genetic: CD19.CAR-aNKT cells;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   Texas Children's Hospital;   The Methodist Hospital System
    Not yet recruiting

  • Conditions:   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent T-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Hodgkin Lymphoma;   Refractory T-Cell Non-Hodgkin Lymphoma
    Interventions:   Drug: Busulfan;   Drug: Gemcitabine;   Drug: Melphalan;   Drug: Olaparib;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacokinetic Study;   Biological: Rituximab;   Drug: Vorinostat
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   NonHodgkin Lymphoma;   Lymphoproliferative Disorders;   EBV Related Lymphoma;   EBV-Related PTLD;   Hodgkin Lymphoma;   EBV Related Non-Hodgkin's Lymphoma;   EBV Related Hodgkin's Lymphoma
    Interventions:   Biological: EBVST Cells;   Biological: Nivolumab
    Sponsors:   Baylor College of Medicine;   The Methodist Hospital System;   Texas Children's Hospital;   Center for Cell and Gene Therapy, Baylor College of Medicine
    Recruiting

  • Conditions:   Lymphoid Malignancies;   Multiple Myeloma;   Lymphoma;   Hodgkin Lymphoma;   Non-hodgkin Lymphoma
    Interventions:   Drug: Pralatrexate;   Drug: Romidepsin
    Sponsor:   Jennifer Amengual
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplastic Syndrome;   Non-hodgkin Lymphoma;   Chronic Lymphocytic Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Other: Haploidentical Stem Cell Transplantation
    Sponsor:   Loyola University
    Recruiting

  • Conditions:   Non-Hodgkin Lymphoma;   Lymphoma;   Diffuse Large B-Cell Lymphoma;   Gray Zone Lymphoma;   Primary Central Nervious System Lymphoma
    Intervention:   Biological: Pembrolizumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Non Hodgkin Lymphoma;   Lymphoma, B-Cell;   High-grade B-cell Lymphoma;   MYC Translocation;   BCL-2 Translocation
    Intervention:   Drug: DA-EPOCH-R followed by Nivolumab
    Sponsor:   Stichting Hemato-Oncologie voor Volwassenen Nederland
    Recruiting

  • Conditions:   Hodgkin Disease;   Non Hodgkin Lymphoma;   Lymphoepithelioma;   Severe Chronic Active EBV Infection Syndrome (SCAEBV);   Leiomyosarcoma
    Interventions:   Drug: LMP1/2 CTLs (Group A);   Drug: LMP1/2 CTLs (Group B)
    Sponsor:   Catherine Bollard
    Recruiting

  • Condition:   Lymphoma, Non-Hodgkin
    Interventions:   Drug: Lenalidomide;   Drug: Rituximab
    Sponsor:   Celgene
    Recruiting

  • Conditions:   Myelodysplastic Syndrome;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Acute Leukemia;   Multiple Myeloma
    Interventions:   Biological: Rituximab;   Drug: Conditioning Chemotherapy;   Drug: TMS;   Drug: FLAG;   Drug: EPOCH-F;   Procedure: Hematopoietic Stem Cell Transplant;   Drug: Palifermin
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Leukemia;   Lymphoma;   Acute Lymphoblastic Leukemia;   Diffuse Large B-Cell Lymphoma;   Non-Hodgkin's Lymphoma
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplastic Syndromes;   Non-Hodgkin Lymphoma;   Hodgkin Disease
    Interventions:   Procedure: Stem cell transplantation;   Drug: Itacitinib;   Other: Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT);   Other: Human Activity Profile
    Sponsors:   Washington University School of Medicine;   Incyte Corporation
    Recruiting

  • Conditions:   Malignancies;   Acute Lymphoblastic Leukemia (ALL);   Acute Myeloid Leukemia (AML);   Non-Hodgkin's Lymphoma;   Neuroblastoma
    Interventions:   Drug: chemotherapy;   Drug: venetoclax
    Sponsors:   AbbVie;   Roche-Genentech
    Recruiting

  • Conditions:   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Transformed Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Transformed Non-Hodgkin Lymphoma;   Richter Syndrome;   Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
    Interventions:   Drug: Atezolizumab;   Drug: Gemcitabine;   Other: Laboratory Biomarker Analysis;   Drug: Oxaliplatin;   Biological: Rituximab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Relapsed or Refractory Haematological Malignancies Including;   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Chronic Lymphocytic Leukemia;   High Risk Myelodysplastic Syndrome;   Chronic Myelomonocytic Leukemia;   Richter's Syndrome;   B-cell Non-Hodgkin Lymphoma;   T-cell Non-Hodgkin Lymphoma;   Small Lymphocytic Lymphoma;   Multiple Myeloma
    Intervention:   Drug: AZD4573
    Sponsor:   AstraZeneca
    Recruiting

  • Conditions:   Waldenstrom Macroglobulinemia;   Chronic Lymphocytic Leukemia;   Hodgkin Disease;   NonHodgkin Lymphoma;   Mixed Lymphoproliferative Disease
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   B-Cell Non-Hodgkin Lymphoma;   Hematopoietic and Lymphoid Cell Neoplasm;   Leukemia;   Lymphoma;   Plasma Cell Myeloma;   T-Cell Non-Hodgkin Lymphoma
    Interventions:   Biological: Ipilimumab;   Drug: Lenalidomide
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Hairy Cell Leukemia (HCL);   Chronic Lymphocytic Leukemia (CLL);   Non-Hodgkins Lymphoma (NHL);   Cutaneous T Cell Lymphoma (CTCL);   Adult T Cell Lymphoma (ATL)
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   CD20 Positive;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Recurrent Transformed Non-Hodgkin Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Transformed Non-Hodgkin Lymphoma
    Interventions:   Drug: Carboplatin;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Biological: Rituximab
    Sponsors:   Academic and Community Cancer Research United;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Leukemia in Remission;   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Acute Myeloid Leukemia With FLT3/ITD Mutation;   Acute Myeloid Leukemia With Gene Mutations;   Aplastic Anemia;   B-Cell Non-Hodgkin Lymphoma;   CD40 Ligand Deficiency;   Chronic Granulomatous Disease;   Chronic Leukemia in Remission;   Chronic Lymphocytic Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Congenital Amegakaryocytic Thrombocytopenia;   Congenital Neutropenia;   Congenital Pure Red Cell Aplasia;   Glanzmann Thrombasthenia;   Immunodeficiency Syndrome;   Myelodysplastic Syndrome;   Myelofibrosis;   Myeloproliferative Neoplasm;   Paroxysmal Nocturnal Hemoglobinuria;   Plasma Cell Myeloma;   Polycythemia Vera;   Recurrent Non-Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndrome;   Severe Aplastic Anemia;   Shwachman-Diamond Syndrome;   Sickle Cell Disease;   T-Cell Non-Hodgkin Lymphoma;   Thalassemia;   Waldenstrom Macroglobulinemia;   Wiskott-Aldrich Syndrome
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Procedure: Peripheral Blood Stem Cell Transplantation;   Radiation: Total-Body Irradiation
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Lymphoma;   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma;   Ann Arbor Stage III T-Cell Non-Hodgkin Lymphoma;   Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma;   Ann Arbor Stage IV T-Cell Non-Hodgkin Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Pancreatic Carcinoma;   Refractory T-Cell Non-Hodgkin Lymphoma;   Stage II Pancreatic Cancer AJCC v8;   Stage IIA Pancreatic Cancer AJCC v8;   Stage IIB Pancreatic Cancer AJCC v8;   Stage III Pancreatic Cancer AJCC v8;   Stage IV Pancreatic Cancer AJCC v8;   Unresectable Pancreatic Carcinoma
    Interventions:   Drug: Entinostat;   Drug: Molibresib
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Chronic Lymphocytic Leukemia;   Diffuse Large B-Cell Lymphoma;   Follicular Lymphoma;   Mantle Cell Lymphoma;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
    Intervention:   Biological: Inactivated Influenza Vaccine
    Sponsor:   Emory University
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia in Remission;   Hematopoietic Cell Transplantation Recipient;   JAK2 Gene Mutation;   Loss of Chromosome 17p;   Mantle Cell Lymphoma;   Minimal Residual Disease;   Myelodysplastic Syndrome;   Non-Hodgkin Lymphoma;   Plasma Cell Myeloma;   RAS Family Gene Mutation;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Hematologic Malignancy;   Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Therapy-Related Acute Myeloid Leukemia;   Therapy-Related Myelodysplastic Syndrome;   TP53 Gene Mutation
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Biological: Irradiated Allogeneic Cells
    Sponsors:   Rutgers, The State University of New Jersey;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Anaplastic Large Cell Lymphoma;   Recurrent Angioimmunoblastic T-cell Lymphoma;   Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma;   Recurrent Mycosis Fungoides;   Recurrent Plasma Cell Myeloma;   Recurrent T-Cell Non-Hodgkin Lymphoma;   Refractory Anaplastic Large Cell Lymphoma;   Refractory Angioimmunoblastic T-cell Lymphoma;   Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory Mycosis Fungoides;   Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified;   Refractory Plasma Cell Myeloma;   Refractory T-Cell Non-Hodgkin Lymphoma
    Interventions:   Biological: Biological Therapy;   Procedure: Computed Tomography;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Procedure: Single Photon Emission Computed Tomography
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Follicular T-Cell Lymphoma;   Grade 1 Follicular Lymphoma;   Grade 2 Follicular Lymphoma;   Grade 3a Follicular Lymphoma;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Recurrent Angioimmunoblastic T-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma;   Recurrent Mycosis Fungoides;   Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory Angioimmunoblastic T-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Stage IB Mycosis Fungoides AJCC v7;   Stage II Mycosis Fungoides AJCC v7;   Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma;   Stage III Mycosis Fungoides AJCC v7;   Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma;   Stage IV Mycosis Fungoides AJCC v7
    Interventions:   Biological: Anti-ICOS Monoclonal Antibody MEDI-570;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Aggressive Non-Hodgkin Lymphoma;   B-Cell Non-Hodgkin Lymphoma;   CD20 Positive;   Diffuse Large B-Cell Lymphoma Unclassifiable;   Intravascular Large B-Cell Lymphoma;   Primary Mediastinal (Thymic) Large B-Cell Lymphoma;   T-Cell/Histiocyte-Rich Large B-Cell Lymphoma;   Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Biological: Nivolumab;   Drug: Prednisone;   Other: Quality-of-Life Assessment;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsors:   Northwestern University;   Bristol-Myers Squibb (BMS);   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Folliculotropic Mycosis Fungoides;   Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma;   Recurrent Mycosis Fungoides;   Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory Mycosis Fungoides;   Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified;   Sezary Syndrome;   Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma
    Interventions:   Biological: Durvalumab;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Recurrent Anaplastic Large Cell Lymphoma;   Recurrent Angioimmunoblastic T-Cell Lymphoma;   Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma;   Recurrent Mycosis Fungoides;   Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory Anaplastic Large Cell Lymphoma;   Refractory Angioimmunoblastic T-Cell Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Refractory Mycosis Fungoides;   Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified;   Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
    Interventions:   Biological: Pembrolizumab;   Drug: Romidepsin
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia (AML);   Acute Lymphocytic Leukemia (ALL);   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myelofibrosis;   Myelodysplasia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Marginal Zone B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Diffuse Large B Cell Lymphoma;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   Non-Hodgkin Lymphoma;   Multiple Myeloma
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Cyclosporine A;   Drug: Mycophenylate mofetil;   Biological: Umbilical cord blood
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Acute Biphenotypic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Ann Arbor Stage I Burkitt Lymphoma;   Ann Arbor Stage I Non-Hodgkin Lymphoma;   Ann Arbor Stage II Burkitt Lymphoma;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Lymphoblastic Lymphoma;   Mantle Cell Lymphoma;   Myelodysplastic Syndrome;   Myelofibrosis;   Pancytopenia;   Plasma Cell Myeloma;   Prolymphocytic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Ann Arbor Stage II Non-Hodgkin Lymphoma;   Ann Arbor Stage III Burkitt Lymphoma;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Burkitt Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   High Risk Acute Myeloid Leukemia;   Progressive Disease;   Refractory Anemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Procedure: Double-Unit Umbilical Cord Blood Transplantation;   Drug: Fludarabine;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation;   Drug: Thiotepa
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Hodgkin's Lymphoma;   Lymphoid Leukemia;   Lymphoma;   Leukemia;   Myeloma;   Acute Lymphocytic Leukemia;   Non Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Multiple Myeloma;   Chronic Myelogenous Leukemia;   Myelodysplastic Syndromes;   Recurrent Acute Myeloid Leukemia, Adult;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Plasma Cell Myeloma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia;   Acute Myelogenous Leukemia
    Interventions:   Drug: mycophenolate mofetil;   Biological: Sargramostim;   Biological: Filgrastim
    Sponsors:   Virginia Commonwealth University;   Massey Cancer Center
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   B-Cell Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Hodgkin Lymphoma;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   T-Cell Non-Hodgkin Lymphoma
    Interventions:   Biological: Anti-Thymocyte Globulin;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Biological: Therapeutic Allogeneic Lymphocytes;   Radiation: Total Nodal Irradiation
    Sponsors:   Robert Lowsky;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   CD19 Positive;   CD22 Positive;   Minimal Residual Disease;   Progressive Disease;   Recurrent B Acute Lymphoblastic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Non-Hodgkin Lymphoma;   Refractory B Acute Lymphoblastic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Refractory Non-Hodgkin Lymphoma
    Interventions:   Biological: Autologous CD19/CD22 Chimeric Antigen Receptor T-cells;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Relapsed or Refractory Hematologic Malignancies;   Non-Hodgkin Lymphoma;   Richter Syndrome;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   T-cell Lymphoma;   Multiple Myeloma;   Acute Myeloid Leukemia (AML);   Acute Lymphocytic Leukemia (ALL);   Myelodysplastic Syndrome (MDS);   Cutaneous T-cell Lymphoma
    Interventions:   Drug: AZD5991;   Drug: AZD5991 + Venetoclax
    Sponsor:   AstraZeneca
    Recruiting

  • Conditions:   AIDS-Related Non-Hodgkin Lymphoma;   Classic Hodgkin Lymphoma;   HIV Infection;   Locally Advanced Malignant Neoplasm;   Locally Advanced Malignant Solid Neoplasm;   Metastatic Malignant Neoplasm;   Metastatic Malignant Solid Neoplasm;   Recurrent Cutaneous Melanoma;   Recurrent Hepatocellular Carcinoma;   Recurrent Hodgkin Lymphoma;   Recurrent Kaposi Sarcoma;   Recurrent Lung Non-Small Cell Carcinoma;   Recurrent Malignant Neoplasm;   Recurrent Non-Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma;   Refractory Malignant Neoplasm;   Refractory Malignant Solid Neoplasm;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIA Hepatocellular Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIB Hepatocellular Carcinoma AJCC v7;   Stage IIIB Lung Non-Small Cell Cancer AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IIIC Hepatocellular Carcinoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Stage IV Lung Non-Small Cell Cancer AJCC v7;   Stage IVA Hepatocellular Carcinoma AJCC v7;   Stage IVB Hepatocellular Carcinoma AJCC v7
    Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Adult Grade III Lymphomatoid Granulomatosis;   B-cell Chronic Lymphocytic Leukemia;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Progressive Hairy Cell Leukemia, Initial Treatment;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Small Lymphocytic Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Small Lymphocytic Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Testicular Lymphoma;   Untreated Hairy Cell Leukemia;   Waldenström Macroglobulinemia
    Interventions:   Drug: lenalidomide;   Drug: etoposide;   Drug: prednisone;   Drug: vincristine sulfate;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Biological: rituximab;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
    Sponsors:   University of Chicago;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Small Cell Lung Cancer;   Uveal Melanoma;   Ovarian Clear Cell Carcinoma;   Non-Hodgkin Lymphoma;   Advanced Malignancies;   Solid Tumor;   Diffuse Large B Cell Lymphoma;   Follicular Lymphoma
    Intervention:   Drug: PLX2853
    Sponsor:   Plexxikon
    Recruiting

  • Conditions:   Aggressive Non-Hodgkin Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-Cell Lymphoma;   Chronic Lymphocytic Leukemia;   Diffuse Large B-Cell Lymphoma;   Enteropathy-Associated T-Cell Lymphoma;   Hepatosplenic T-Cell Lymphoma;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Mediastinal (Thymic) Large B-Cell Lymphoma;   Nasal Type Extranodal NK/T-Cell Lymphoma;   Peripheral T-Cell Lymphoma, Not Otherwise Specified;   Primary Cutaneous Anaplastic Large Cell Lymphoma;   Refractory Anaplastic Large Cell Lymphoma;   Small Lymphocytic Lymphoma;   Subcutaneous Panniculitis-Like T-Cell Lymphoma
    Interventions:   Dietary Supplement: Cholecalciferol;   Other: Laboratory Biomarker Analysis
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndromes;   Myelofibrosis;   Relapsed Non-Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma;   Relapsed Chronic Lymphocytic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Lymphoid Malignancies;   Chronic Myelogenous Leukemia
    Interventions:   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Procedure: mesenchymal stem cell transplantation
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Juvenile Myelomonocytic Leukemia;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: Fludarabine phosphate;   Drug: Thiotepa;   Radiation: Total body irradiation;   Biological: Therapeutic allogeneic lymphocytes;   Drug: Cyclophosphamide;   Procedure: Allogeneic hematopoietic stem cell transplantation (HSCT);   Procedure: Peripheral blood stem cell transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   Metastatic Melanoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Rhabdomyosarcoma;   Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Refractory Hodgkin Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Melanoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Rhabdomyosarcoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7
    Interventions:   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Melanoma;   Non-small Cell Lung Cancer;   Breast Cancer;   Gastric Cancer;   Renal Cell Carcinoma;   Ovarian Cancer;   Cholangiocarcinoma;   Bladder Urothelial Carcinoma;   Pancreatic Adenocarcinoma;   Colorectal Cancer;   Esophageal Cancer;   Hepatic Cancer;   Head and Neck Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer;   Other Solid Tumors;   Diffuse Large B-cell Lymphoma (DLBCL);   Mantle Cell Lymphoma;   Indolent B-cell Lymphomas;   Non-Hodgkin Lymphoma
    Interventions:   Drug: CDX-1140;   Drug: CDX-301
    Sponsor:   Celldex Therapeutics
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Biphenotypic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma;   High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   ISS Stage II Plasma Cell Myeloma;   ISS Stage III Plasma Cell Myeloma;   Myelodysplastic Syndrome;   Recurrent Acute Lymphoblastic Leukemia;   Recurrent Acute Myeloid Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Acute Lymphoblastic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Small Lymphocytic Lymphoma;   Secondary Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia;   Therapy-Related Myelodysplastic Syndrome
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Biological: Natural Killer Cell Therapy;   Biological: Rituximab;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Other Diseases of Blood and Blood-forming Organs;   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myeloid Leukemia;   Chronic Lymphocytic Leukemia;   Myelodysplastic Syndrome;   Myeloproliferative Syndrome;   Non-Hodgkins Lymphoma;   Hodgkins Lymphoma;   Multiple Myeloma
    Interventions:   Drug: Busulfan;   Drug: Thiotepa;   Drug: Fludarabine monophosphate;   Procedure: Stem Cell Infusion;   Drug: Mesna;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Drug: G-CSF
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   HIV Infection;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Plasmablastic Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Follicular Lymphoma;   Stage III Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Biological: Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation
    Sponsors:   AIDS Malignancy Consortium;   National Cancer Institute (NCI);   California Institute for Regenerative Medicine (CIRM)
    Recruiting

  • Conditions:   ALK Positive;   BCL6 Positive;   Recurrent Anaplastic Large Cell Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Transformed Non-Hodgkin Lymphoma;   Refractory Anaplastic Large Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Mantle Cell Lymphoma;   Refractory Transformed Non-Hodgkin Lymphoma
    Intervention:   Drug: Onalespib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   ALK-Positive Large B-Cell Lymphoma;   Atypical Burkitt/Burkitt-Like Lymphoma;   Burkitt-Like Lymphoma With 11q Aberration;   Diffuse Large B-Cell Lymphoma Activated B-Cell Type;   Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation;   Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   EBV-Positive Mucocutaneous Ulcer;   High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements;   High Grade B-Cell Lymphoma, Not Otherwise Specified;   Human Herpesvirus 8-Positive Neoplastic Cells Present;   Intravascular Large B-Cell Lymphoma;   Large B-Cell Lymphoma With IRF4 Rearrangement;   Plasmablastic Lymphoma;   Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type;   Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System;   Primary Effusion Lymphoma;   Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Lymphomatoid Granulomatosis;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Burkitt Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Small Intestinal High Grade B-Cell Lymphoma, Not Otherwise Specified;   T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
    Interventions:   Biological: Nivolumab;   Drug: Varlilumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Non-Hodgkin Lymphoma;   Burkitt Lymphoma;   Diffuse Large B-Cell Lymphoma;   Primary Mediastinal B-cell Lymphoma;   CD20+ Lymphoblastic Lymphoma;   Follicular Lymphoma, Grade III
    Interventions:   Drug: Obinutuzumab;   Drug: Liposomal ARA-C;   Drug: Ifosfamide;   Drug: Carboplatin;   Drug: Etoposide
    Sponsors:   New York Medical College;   Roswell Park Cancer Institute
    Recruiting

  • Conditions:   Acute Leukemia;   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Lymphoma;   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myeloproliferative Neoplasms;   Myelofibrosis;   Myelodysplasia;   Refractory Anemia;   High Risk Anemia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Marginal Zone B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Diffuse Large Cell Non Hodgkins Lymphoma;   Lymphoblastic Lymphoma;   Burkitt Lymphoma;   High Grade Non-Hodgkin's Lymphoma, Adult;   Multiple Myeloma;   Juvenile Myelomonocytic Leukemia;   Biphenotypic/Undifferentiated/Prolymphocytic Leukemias;   MRD Positive Leukemia;   Natural Killer Cell Malignancies;   Acquired Bone Marrow Failure Syndromes
    Interventions:   Biological: HSCT with TBI Regimen;   Biological: HSCT with Non-TBI Regimen
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Hematological Malignancy;   Acute Leukemia in Remission;   Acute Lymphoblastic Leukemia in Remission;   Myelodysplastic Syndromes;   Non-Hodgkin Lymphoma;   Hodgkin Lymphoma
    Interventions:   Biological: Cord blood stem cells;   Drug: Valproic Acid;   Drug: Fludarabine;   Drug: cytoxan;   Drug: Thiotepa;   Biological: TBI
    Sponsor:   Alla Keyzner
    Recruiting

  • Conditions:   Acute Lymphoid Leukemia (ALL);   Acute Myeloid Leukemia (AML);   Chronic Myeloid Leukemia (CML);   Hodgkin Lymphoma;   Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia
    Interventions:   Radiation: Hyperfractionated total body irradiation;   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Clofarabine;   Procedure: HPC(A) stem cell allograft;   Drug: Rituximab;   Device: Rabbit antithymocyte globulin
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Chronic Lymphocytic Leukemia (CLL);   Multiple Myeloma;   Acute Myeloid Leukemia (AML);   Non-Hodgkin's Lymphoma;   Acute Lymphoblastic Leukemia (ALL);   Amyloidosis
    Intervention:   Drug: Venetoclax
    Sponsor:   AbbVie
    Available

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome;   Chronic Myelogenous Leukemia;   Non-Hodgkin Lymphoma;   Hodgkin Lymphoma
    Interventions:   Radiation: Radiation;   Drug: Cyclophosphamide;   Biological: Donor Lymphocyte Infusion (DLI);   Biological: Haploidentical Stem Cell Transplantation
    Sponsors:   Northwell Health;   New York Blood Center
    Recruiting

  • Conditions:   AML - Acute Myeloid Leukemia;   MDS (Myelodysplastic Syndrome);   Mixed Phenotype Acute Leukemia;   NHL - Non-Hodgkin's Lymphoma;   Hodgkin's Lymphoma;   ALL
    Intervention:   Biological: T-allo10
    Sponsor:   Stanford University
    Recruiting

  • Conditions:   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Aplastic Anemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Myelodysplastic Syndromes;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Juvenile Myelomonocytic Leukemia;   Mastocytosis;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Polycythemia Vera;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia;   Refractory Anemia With Ringed Sideroblasts;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Waldenström Macroglobulinemia
    Interventions:   Drug: Fludarabine;   Drug: Busulfan;   Radiation: Total Body Irradiation (TBI);   Biological: Donor Lymphocyte Infusion (DLI);   Drug: Cyclophosphamide (CY);   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Device: Allogeneic hematopoietic stem cell transplantation;   Procedure: Peripheral blood stem cell transplantation (PBSCT)
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   Malignancy;   Non-hodgkin Lymphoma;   Multiple Myeloma;   Breast Cancer;   Ovarian Cancer;   Soft Tissue Sarcoma;   Squamous Cell Carcinoma;   Head and Neck Cancer;   DLBCL;   Mantle Cell Lymphoma;   Follicular Lymphoma;   Leiomyosarcoma;   Pancreatic Cancer;   Sarcoma;   CLL
    Intervention:   Drug: CYT-0851
    Sponsor:   Cyteir Therapeutics, Inc.
    Not yet recruiting

  • Conditions:   B-cell Lymphoma;   Non Hodgkin Lymphoma;   Multiple Myeloma;   Follicular Lymphoma;   Mantle Cell Lymphoma;   Diffuse Large B Cell Lymphoma;   Indolent Lymphoma;   B Cells--Tumors
    Intervention:   Drug: STRO-001
    Sponsor:   Sutro Biopharma, Inc.
    Recruiting

  • Condition:   Primary Central Nervous System Lymphoma
    Interventions:   Drug: Rituximab;   Drug: Methotrexate;   Drug: Procarbazine;   Drug: Lenalidomide;   Radiation: Radiotherapy;   Drug: Temozolomide
    Sponsor:   International Extranodal Lymphoma Study Group (IELSG)
    Recruiting

  • Condition:   Diffuse Large B-Cell Lymphoma
    Interventions:   Drug: Enzastaurin Hydrochloride;   Other: R-CHOP + placebo
    Sponsor:   Denovo Biopharma LLC
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndromes;   Non-hodgkin Lymphoma;   Hodgkin Lymphoma;   Acquired Aplastic Anemia;   Sickle Cell Disease
    Intervention:   Other: Donor Search Prognosis Score
    Sponsors:   Center for International Blood and Marrow Transplant Research;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network;   National Marrow Donor Program;   Medical College of Wisconsin
    Recruiting

  • Conditions:   Hematologic Diseases;   Acute Myeloid Leukemia in Remission;   Acute Lymphoblastic Leukemia in Remission;   Chronic Myelogenous Leukemia - Chronic Phase;   Chronic Myelogenous Leukemia, Accelerated Phase;   Chronic Myelogenous Leukemia, Blastic Phase;   Myelodysplastic Syndromes;   Mantle Cell Lymphoma;   Follicular Lymphoma;   Diffuse Large B Cell Lymphoma;   Non Hodgkin Lymphoma;   Graft Vs Host Disease;   Graft-versus-host-disease
    Interventions:   Drug: Vorinostat;   Procedure: Blood and Marrow Transplant (BMT);   Drug: Tacrolimus;   Drug: Methotrexate
    Sponsor:   University of Michigan Rogel Cancer Center
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Acute Myeloid Leukemia in Remission;   Aplastic Anemia;   Bone Marrow Failure;   Chronic Lymphocytic Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Donor;   Follicular Lymphoma;   Hematopoietic Cell Transplantation Recipient;   Hodgkin Lymphoma;   Mantle Cell Lymphoma;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Near Complete Response of Multiple Myeloma or Plasma Cell Leukemia;   Non-Hodgkin Lymphoma;   Partial Response of Multiple Myeloma or Plasma Cell Leukemia;   Plasma Cell Myeloma
    Interventions:   Biological: Anti-Thymocyte Globulin;   Drug: Cyclophosphamide;   Biological: Cytokine-treated Veto Cells;   Drug: Fludarabine;   Procedure: Peripheral Blood Stem Cell Transplantation;   Radiation: Total-Body Irradiation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Hodgkin Lymphoma;   Non-Hodgkin Lymphoma;   Myelodysplastic Syndrome;   Myeloproliferative Syndrome;   Rhabdomyosarcoma;   Ewing Sarcoma;   Primitive Neuroectodermal Tumor;   Osteosarcoma;   Neuroblastoma
    Interventions:   Procedure: TCRαβ+/CD19+ depleted Haploidentical HSCT;   Drug: Zoledronate
    Sponsor:   University of Wisconsin, Madison
    Recruiting

  • Condition:   Mature B-Cell Lymphoma
    Interventions:   Drug: COPAD;   Drug: COP, COPD M3, CYM;   Drug: COP, COPADM8, CYVE
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Hodgkin Lymphoma;   Lymphoid Leukemia;   Multiple Myeloma;   Myeloid Leukemia;   Monocytic Leukemia;   Non Hodgkin Lymphoma;   Myelodysplasia
    Intervention:   Drug: Intravenous (IV) and oral Vitamin C
    Sponsor:   Virginia Commonwealth University
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Chronic Lymphocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Cytomegalovirus Positive;   Hematopoietic Cell Transplant Recipient;   Hodgkin Lymphoma;   Lymphadenopathy;   Lymphoblastic Lymphoma;   Myelodysplastic Syndrome;   Myelofibrosis;   Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma
    Interventions:   Drug: Letermovir;   Biological: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine;   Other: Placebo
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Blasts More Than 5 Percent of Bone Marrow Nucleated Cells;   Blasts More Than 5 Percent of Peripheral Blood White Cells;   CD19 Positive;   Chronic Lymphocytic Leukemia;   Minimal Residual Disease;   Non-Hodgkin Lymphoma;   Small Lymphocytic Lymphoma
    Interventions:   Biological: Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsors:   M.D. Anderson Cancer Center;   Ziopharm Oncology
    Not yet recruiting

  • Conditions:   Acute Myeloid Leukemia in Remission;   Myelodysplastic Syndromes;   Chronic Myeloid Leukemia in Remission;   Myeloproliferative Syndrome;   Myeloproliferative Disorder;   Acute Lymphoid Leukemia in Remission;   Multiple Myeloma;   Chronic Lymphoid Leukemia;   Non Hodgkin Lymphoma;   Hodgkin Lymphoma
    Interventions:   Drug: Thymoglobulin;   Drug: Melphalan;   Drug: Fludarabine
    Sponsors:   University of Liege;   Belgian Hematological Society Transplant Committee
    Recruiting

  • Conditions:   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myelodysplastic Syndromes;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   Non-Hodgkin's Lymphoma;   Multiple Myeloma;   Myeloproliferative Syndromes;   Hematological Diseases
    Interventions:   Drug: Allopurinol;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: ATG;   Radiation: TBI;   Drug: Tacrolimus;   Drug: MMF;   Biological: Peripheral Blood Stem Cells;   Biological: Related or Unrelated Bone Marrow Cells
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndromes;   Myeloproliferative Disorder;   Chronic Lymphocytic Leukemia;   B-cell Lymphoma;   T-cell Lymphoma;   Non Hodgkin Lymphoma;   Hodgkin Lymphoma;   Chronic Myelomonocytic Leukemia
    Interventions:   Radiation: Total body irradiation (TBI);   Drug: Anti-thymocyte globulin (ATG);   Drug: Tacrolimus;   Drug: Mycophenolate mofetil (MMF);   Radiation: Total lymphoid irradiation (TLI)
    Sponsor:   Stanford University
    Recruiting

  • Conditions:   Acute Erythroid Leukemia;   Acute Lymphoblastic Leukemia;   Acute Megakaryoblastic Leukemia;   Acute Myeloid Leukemia;   Blasts Under 10 Percent of Bone Marrow Nucleated Cells;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Hematopoietic and Lymphoid Cell Neoplasm;   Human Immunodeficiency Virus Positive;   Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts;   Non-Hodgkin Lymphoma;   Refractory Anemia
    Interventions:   Drug: Fludarabine;   Drug: Fludarabine Phosphate;   Drug: Cyclophosphamide;   Drug: Thiotepa;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation;   Other: Cellular Therapy
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Not yet recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Chronic Lymphocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Cytomegalovirus Positive;   Donor;   Hematopoietic Cell Transplant Recipient;   Hodgkin Lymphoma;   Myelodysplastic Syndrome;   Myelodysplastic/Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma;   Myelofibrosis;   Hematopoietic and Lymphoid Cell Neoplasm
    Intervention:   Biological: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Adenocarcinoma;   Adenocystic Carcinoma;   Anal Cancer;   Appendix Cancer;   Brain Tumor;   Glioblastoma;   Astrocytoma;   Bile Duct Cancer;   Cholangiocarcinoma;   Bladder Cancer;   Bone Cancer;   Synovial Sarcoma;   Chondrosarcoma;   Liposarcoma;   Sarcoma, Kaposi;   Sarcoma,Soft Tissue;   Sarcoma;   Osteosarcoma;   CNS Cancer;   Brain Stem Neoplasms;   Breast Cancer;   Cervical Cancer;   Colorectal Cancer;   Rectal Cancer;   Colon Cancer;   Esophageal Cancer;   Esophagus Cancer;   Cancer of Colon;   Pancreatic Cancer;   Cancer of Pancreas;   Testis Cancer;   Testicular Cancer;   Ureter Cancer;   Renal Cell Carcinoma;   Kidney Cancer;   Gestational Trophoblastic Tumor;   Head and Neck Neoplasms;   Parotid Tumor;   Larynx Cancer;   Tongue Cancer;   Pharynx Cancer;   Salivary Gland Cancer;   Acute Myeloid Leukemia;   Chronic Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Multiple Myeloma;   Non Hodgkin Lymphoma;   Carcinoid Tumor;   Lung Cancer;   Neuroendocrine Tumors;   Mesothelioma;   Thyroid Cancer;   Parathyroid Neoplasms;   Adrenal Cancer;   Small Bowel Cancer;   Stomach Cancer;   Liver Cancer;   Hepatic Cancer;   Melanoma;   Skin Cancer;   Unknown Primary Tumors;   Uterine Cancer;   Fallopian Tube Cancer;   Ovarian Cancer;   Prostate Cancer;   Vaginal Cancer;   Penile Cancer;   Vulvar Cancer;   Waldenstrom Macroglobulinemia;   Cancer, Advanced;   Thymus Cancer;   Nasopharyngeal Carcinoma;   Multiple Endocrine Neoplasia;   Pheochromocytoma;   Small Cell Carcinoma;   Pulmonary Carcinoma
    Interventions:   Diagnostic Test: Testing: Genome;   Diagnostic Test: Testing: Transcriptome;   Diagnostic Test: Testing: Proteome;   Drug: Treatment: CAR-T
    Sponsor:   Taproot Health
    Not yet recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Acute Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic-Myeloproliferative Diseases;   Myeloproliferative Disorder;   Non Hodgkin Lymphoma;   Hodgkin Lymphoma;   Leukemia
    Interventions:   Radiation: Total Body Irradiation;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil;   Drug: Tocilizumab;   Drug: Filgrastim
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Non-Hodgkin's Lymphoma;   Hodgkin's Disease;   Multiple Myeloma;   Germ Cell Neoplasms;   Myelodysplastic Syndromes;   Chronic Lymphocytic Leukemia;   Immunodeficiency Diseases
    Intervention:  
    Sponsor:   Wake Forest University Health Sciences
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome;   Acute Lymphoblastic Leukemia;   Chronic Myeloid Leukemia;   Chronic Lymphocytic Leukemia;   Non Hodgkin Lymphoma;   Hodgkin Lymphoma;   Myeloproliferative Syndromes;   Plasma Cell Myeloma;   Colon Carcinoma;   Adenocarcinoma of Rectum;   Soft Tissue Sarcoma;   Ewing's Sarcoma;   Rhabdomyosarcoma
    Interventions:   Biological: Natural Killer (NK) Cells;   Biological: ALT803
    Sponsor:   David Wald
    Recruiting

  • Conditions:   Acute Myeloid Leukemia in Remission;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission;   Chronic Myelomonocytic Leukemia in Remission;   Graft Versus Host Disease;   Hodgkin Lymphoma;   Minimal Residual Disease;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma;   Plasma Cell Myeloma;   Severe Aplastic Anemia;   Waldenstrom Macroglobulinemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan Hydrochloride;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Lung Neoplasms;   Carcinoma, Non-Small-Cell Lung;   Carcinoma, Small Cell;   Malignant Mesothelioma, Advanced;   Head and Neck Cancer;   Melanoma;   Merkel Cell Carcinoma;   Renal Cell Carcinoma;   Urothelial Carcinoma;   Classical Hodgkin Lymphoma;   Colorectal Cancer;   Cutaneous Squamous Cell Carcinoma;   Non Hodgkin Lymphoma;   Endometrial Cancer
    Intervention:   Drug: CK-301 (cosibelimab)
    Sponsors:   Checkpoint Therapeutics, Inc.;   Novotech (Australia) Pty Limited
    Recruiting

  • Conditions:   Acute Leukemia;   Adenomatous Polyposis;   Adrenocortical Carcinoma;   AML;   BAP1 Tumor Predisposition Syndrome;   Carney Complex;   Choroid Plexus Carcinoma;   Constitutional Mismatch Repair Deficiency Syndrome;   Diamond-Blackfan Anemia;   DICER1 Syndrome;   Dyskeratosis Congenita;   Emberger Syndrome;   Familial Acute Myeloid Leukemia;   Familial Adenomatous Polyposis;   Fanconi Anemia;   Familial Cancer;   Familial Wilms Tumor;   Familial Neuroblastoma;   GIST;   Hereditary Breast and Ovarian Cancer;   Hereditary Paraganglioma-Pheochromocytoma Syndrome;   Hodgkin Lymphoma;   Juvenile Polyposis;   Li-Fraumeni Syndrome;   Lynch Syndrome;   MDS;   Melanoma Syndrome;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2;   Neuroblastoma;   Neurofibromatosis Type 1;   Neurofibromatosis Type II;   Nevoid Basal Cell Carcinoma Syndrome;   Non Hodgkin Lymphoma;   Noonan Syndrome and Other Rasopathy;   Overgrowth Syndromes;   Pancreatic Cancer;   Peutz-Jeghers Syndrome;   Pheochromocytoma/Paraganglioma;   PTEN Hamartoma Tumor Syndrome;   Retinoblastoma;   Rhabdoid Tumor Predisposition Syndrome;   Rhabdomyosarcoma;   Rothmund-Thomson Syndrome;   Tuberous Sclerosis;   Von Hippel-Lindau Disease
    Intervention:  
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Non-Small Cell Lung Cancer;   Renal Cell Cancer;   Colorectal Cancer;   Triple Negative Breast Cancer;   Cervical Cancer;   Ovarian Cancer;   Pancreatic Cancer;   Endometrial Cancer;   Sarcoma;   Squamous Cell Carcinoma of the Head and Neck;   Bladder Cancer;   Metastatic Castration Resistant Prostate Cancer;   Non-hodgkin Lymphoma
    Interventions:   Drug: CPI-006;   Drug: CPI-006 + CPI-444;   Drug: CPI-006 + pembrolizumab
    Sponsor:   Corvus Pharmaceuticals, Inc.
    Recruiting

  • Conditions:   Cancer, Metastatic;   Cancer;   Cancer of Pancreas;   Cancer of Liver;   Cancer of Stomach;   Cancer Liver;   Cancer of Rectum;   Cancer of Kidney;   Cancer of Esophagus;   Cancer of Cervix;   Cancer of Colon;   Cancer of Larynx;   Cancer, Lung;   Cancer, Breast;   Cancer, Advanced;   Cancer Prostate;   Cancer of Neck;   Cancer of Skin;   Neuroendocrine Tumors;   Carcinoma;   Mismatch Repair Deficiency;   BRCA Gene Rearrangement;   Non Hodgkin Lymphoma;   Leukemia;   Non Small Cell Lung Cancer;   Cholangiocarcinoma;   Glioblastoma;   Central Nervous System Tumor;   Melanoma;   Urothelial Carcinoma;   Bladder Cancer;   Ovarian Cancer;   Endometrial Cancer;   Testicular Cancer;   Breast Cancer
    Intervention:   Other: Clinical Trial Matching
    Sponsor:   Massive Bio, Inc.
    Recruiting

  • Conditions:   Breast Cancer;   Colorectal Cancer;   Cholangiocellular Carcinoma;   Sarcoma;   Desmoid Tumour;   Adenoid Cystic Carcinoma;   Non-hodgkin Lymphoma;   Glomus Tumor, Malignant
    Intervention:   Drug: CB-103
    Sponsor:   Cellestia Biotech AG
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Aggressive Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Diffuse Large B-Cell Lymphoma;   Hematopoietic Cell Transplant Recipient;   Loss of Chromosome 17p;   Mantle Cell Lymphoma;   Myelodysplastic Syndrome;   Myelodysplastic/Myeloproliferative Neoplasm;   Prolymphocytic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Hodgkin Lymphoma;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Recurrent Waldenstrom Macroglobulinemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Chronic Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Acute Biphenotypic Leukemia;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma;   Hodgkins Disease;   Chronic Lymphocytic Leukemia;   Multiple Myeloma
    Interventions:   Drug: tacrolimus;   Drug: methotrexate;   Drug: Mycophenolate mofetil;   Drug: Methotrexate (low dose)
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Hematologic Malignancies;   Inherited Disorders of Metabolism;   Inherited Abnormalities of Platelets;   Histiocytic Disorders;   Acute Myelogenous Leukemia (AML or ANLL);   Acute Lymphoblastic Leukemia (ALL);   Other Acute Leukemia;   Chronic Myelogenous Leukemia (CML);   Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases;   Other Leukemia;   Hodgkin Lymphoma;   Non-hodgkin Lymphoma;   Multiple Myeloma/ Plasma Cell Disorder (PCD);   Inherited Abnormalities of Erythrocyte Differentiation or Function;   Disorders of the Immune System;   Automimmune Diseases;   Severe Aplastic Anemia
    Intervention:   Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
    Sponsors:   Center for International Blood and Marrow Transplant Research;   National Marrow Donor Program
    Recruiting

  • Condition:   Lymphoma
    Intervention:   Drug: Parsaclisib
    Sponsor:   Incyte Corporation
    Recruiting

  • Conditions:   Brain Tumors and/or Solid Tumors Including;   Brain Stem Glioma;   High Grade CNS Tumors;   Ependymoma;   Medulloblastoma;   Craniopharyngioma;   Low Grade CNS Tumors;   Hodgkin Lymphoma;   Non Hodgkin Lymphoma;   Ewing Sarcoma;   Osteosarcoma;   Rhabdomyosarcoma;   Neuroblastoma;   Other
    Intervention:   Drug: Methionine
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   B-Cell Non-Hodgkin Lymphoma;   Chemotherapy-Related Nausea and/or Vomiting;   Childhood Acute Myeloid Leukemia;   Childhood Burkitt Lymphoma;   Childhood Neoplasm;   Febrile Neutropenia;   Hematopoietic Cell Transplant Recipient;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Other: Informational Intervention;   Other: Interview;   Other: Medical Chart Review;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Biphenotypic Leukemia;   Acute Lymphoblastic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia With Myelodysplasia-Related Changes;   Acute Myeloid Leukemia With Variant MLL Translocations;   B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1;   Chemotherapy-Related Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   ISS Stage II Plasma Cell Myeloma;   ISS Stage III Plasma Cell Myeloma;   Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts;   Myelodysplastic Syndrome With Gene Mutation;   Myelodysplastic/Myeloproliferative Neoplasm;   Previously Treated Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Refractory Acute Lymphoblastic Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia;   Secondary Acute Myeloid Leukemia;   Therapy-Related Myelodysplastic Syndrome
    Interventions:   Biological: Allogeneic Natural Killer Cell Line NK-92;   Biological: Anti-Thymocyte Globulin;   Drug: Busulfan;   Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Biological: Rituximab;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Hodgkin Lymphoma;   Adult Non-Hodgkin Lymphoma;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Cytomegaloviral Infection;   Hematopoietic and Lymphoid Cell Neoplasm;   HLA-A*0201 Positive Cells Present;   Myelodysplastic Syndrome;   Adult Lymphoblastic Lymphoma;   Chronic Lymphocytic Leukemia;   Myelofibrosis;   Myeloproliferative Neoplasm
    Interventions:   Biological: CMVpp65-A*0201 peptide vaccine;   Other: Placebo;   Other: Laboratory Biomarker Analysis
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Blasts 5 Percent or Less of Bone Marrow Nucleated Cells;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Donor;   Minimal Residual Disease;   Myelodysplastic Syndrome;   Myelofibrosis;   Myeloproliferative Neoplasm;   Recurrent Acute Myeloid Leukemia;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Refractory Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia
    Interventions:   Biological: Anti-Thymocyte Globulin;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Drug: Methotrexate;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Cancer;   Lymphoma;   Pancreatic Cancer;   Glioblastoma Multiforme;   Sarcoma;   Breast Cancer;   Bladder Cancer;   Renal Cancer;   Ovarian Cancer;   Refractory Cancer;   Refractory Neoplasm;   Refractory Non-Hodgkin Lymphoma;   Refractory Brain Tumor;   Pancreatic Adenocarcinoma;   Resistant Cancer;   Neoplasm Metastasis;   Neoplasm of Bone;   Neoplasm, Breast;   Neoplasm of Lung;   Neoplasms,Colorectal;   Neoplasms Pancreatic;   Malignant Glioma;   Malignancies;   Malignancies Multiple;   Bone Metastases;   Bone Neoplasm;   Bone Cancer;   Pancreas Cancer;   Pancreatic Neoplasms;   Breast Neoplasms
    Interventions:   Drug: 9-ING-41;   Drug: Gemcitabine - 21 day cycle;   Drug: Doxorubicin.;   Drug: Lomustine;   Drug: Carboplatin.;   Drug: Nab paclitaxel.;   Drug: Paclitaxel.;   Drug: Gemcitabine - 28 day cycle
    Sponsors:   Actuate Therapeutics Inc.;   Developmental Therapeutics Consortium
    Recruiting

  • Conditions:   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   Aplastic Anemia;   Blasts Under 10 Percent of Bone Marrow Nucleated Cells;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelomonocytic Leukemia;   Hematopoietic Cell Transplantation Recipient;   Minimal Residual Disease;   Myeloproliferative Neoplasm;   Plasma Cell Myeloma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Therapy-Related Myelodysplastic Syndrome
    Interventions:   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation;   Biological: Rituximab;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Myeloid Leukemia in Remission;   Aplastic Anemia;   Chronic Myelomonocytic Leukemia;   Hodgkin Lymphoma;   Indolent Non-Hodgkin Lymphoma;   Malignant Neoplasm;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Plasma Cell Myeloma;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ring Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
    Interventions:   Drug: Fludarabine;   Radiation: Total-Body Irradiation;   Biological: T Cell-Depleted Donor Lymphocyte Infusion;   Drug: Cyclophosphamide;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   CD19 Positive;   Mantle Cell Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Melphalan;   Biological: Rituximab;   Biological: Umbilical Cord Blood-derived Natural Killer Cells
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Acute Lymphoblastic Leukemia (ALL);   Acute Myeloid Leukemia (AML);   Myelodysplastic Syndromes (MDS);   NK-Cell Leukemia;   Hodgkin Lymphoma;   Non Hodgkin Lymphoma (NHL);   Juvenile Myelomonocytic Leukemia (JMML);   Chronic Myeloid Leukemia (CML)
    Interventions:   Drug: Cyclophosphamide;   Biological: Fludarabine;   Drug: Thiotepa;   Drug: Melphalan;   Biological: G-csf;   Drug: Mesna;   Device: CliniMACS;   Biological: ATG (rabbit);   Drug: Blinatumomab;   Biological: TCRα/β+;   Biological: CD19+;   Biological: CD45RA-depleted DLI
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia (ALL);   Acute Myeloid Leukemia (AML);   Myeloid Sarcoma;   Chronic Myeloid Leukemia (CML);   Juvenile Myelomonocytic Leukemia (JMML);   Myelodysplastic Syndrome (MDS);   Non-Hodgkin Lymphoma (NHL)
    Interventions:   Drug: Anti-thymocyte globulin (rabbit);   Drug: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: G-CSF;   Drug: Melphalan;   Drug: Mesna;   Drug: Rituximab;   Drug: Tacrolimus;   Drug: Thiotepa;   Biological: HPC,A Infusion;   Device: CliniMACS;   Drug: Sirolimus
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Adult T-Cell Leukemia/Lymphoma;   Anaplastic Large Cell Lymphoma, ALK-Negative;   Anaplastic Large Cell Lymphoma, ALK-Positive;   Angioimmunoblastic T-Cell Lymphoma;   Ann Arbor Stage II Noncutaneous Anaplastic Large Cell Lymphoma;   Ann Arbor Stage III Noncutaneous Anaplastic Large Cell Lymphoma;   Ann Arbor Stage IV Noncutaneous Anaplastic Large Cell Lymphoma;   CD30-Positive Neoplastic Cells Present;   Enteropathy-Associated T-Cell Lymphoma;   Hepatosplenic T-Cell Lymphoma;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Peripheral T-Cell Lymphoma, Not Otherwise Specified
    Interventions:   Drug: Brentuximab Vedotin;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Lymphoma
    Intervention:   Drug: Parsaclisib
    Sponsor:   Incyte Corporation
    Recruiting

  • Condition:   Lymphoma
    Intervention:   Drug: Parsaclisib
    Sponsor:   Incyte Corporation
    Recruiting

  • Condition:   Malignant Hematologic Neoplasm
    Intervention:   Procedure: Parenteral Nutrition/Enteral Nutrition
    Sponsor:   Lawson Health Research Institute
    Not yet recruiting

  • Condition:   Hematologic Malignancies
    Interventions:   Drug: Venetoclax;   Drug: ethinyl estradiol/levonorgestrel
    Sponsor:   AbbVie
    Recruiting

  • Condition:   Lymphoma
    Intervention:   Drug: AG-636
    Sponsor:   Agios Pharmaceuticals, Inc.
    Recruiting

  • Conditions:   Lymphoma, Non-Hodgkin;   Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Follicular
    Interventions:   Biological: JCAR017;   Drug: Durvalumab;   Drug: CC-122
    Sponsors:   Celgene;   Juno Therapeutics, Inc.
    Recruiting

  • Condition:   Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL)
    Intervention:   Other: blood sample
    Sponsor:   University Hospital, Limoges
    Recruiting

  • Condition:   Relapsed and/or Refractory Non-Hodgkin T-cell Lymphoma
    Intervention:   Drug: Lenalidomide 25mg
    Sponsor:   Samsung Medical Center
    Recruiting

  • Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Nonmalignant Neoplasm
    Interventions:   Other: biologic sample preservation procedure;   Other: cytology specimen collection procedure
    Sponsors:   UNC Lineberger Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Brain and Central Nervous System Tumors;   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Unspecified Adult Solid Tumor, Protocol Specific
    Intervention:   Device: 3'-deoxy-3'-[18F]fluorothymidine
    Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Relapsed Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
    Interventions:   Drug: INCB053914;   Drug: INCB050465
    Sponsor:   Incyte Corporation
    Recruiting

  • Conditions:   Follicular Lymphoma;   Mantle Cell Lymphoma
    Intervention:   Drug: Ribavirin
    Sponsor:   Weill Medical College of Cornell University
    Recruiting

  • Condition:   Hematologic Cancer
    Intervention:   Other: Molecularly targeted treatment matched to genomic/immunophenotypic tumor profile (chosen by treating physician)
    Sponsor:   University of California, San Diego
    Recruiting

  • Conditions:   Peripheral T-Cell Lymphoma (PTCL NOS);   Nodal Lymphomas of T Follicular Helper (TFH);   Follicular T-cell Lymphoma (FTCL);   AITL;   ALCL;   HSTCL;   EATL I,II;   MEITL, EATL Type II;   Nasal Lymphoma
    Intervention:   Drug: Cerdulatinib
    Sponsor:   Portola Pharmaceuticals
    Not yet recruiting

  • Condition:   Lymphoma, Non-Hodgkin
    Interventions:   Drug: Nivolumab;   Drug: Rituximab;   Drug: Gemcitabine;   Device: Oxaliplatin
    Sponsors:   University Hospital, Saarland;   Bristol-Myers Squibb;   Lymphoma Study Association;   University of Leipzig
    Recruiting

  • Conditions:   Diffuse Large B-Cell Lymphoma;   High Grade B-Cell Lymphoma
    Interventions:   Drug: Venetoclax;   Drug: Rituximab;   Drug: Etoposide;   Drug: Vincristine Sulfate;   Drug: Cyclophosphamide;   Drug: Prednisone;   Drug: Doxorubicin Hydrochloride
    Sponsors:   Weill Medical College of Cornell University;   Genentech, Inc.;   Massachusetts General Hospital;   M.D. Anderson Cancer Center
    Recruiting

  • Condition:   Lymphoma, Mantle Cell
    Interventions:   Drug: Acalabrutinib in combination with bendamustine and rituximab;   Drug: Placebo in combination with bendamustine and rituximab
    Sponsor:   Acerta Pharma BV
    Recruiting

  • Condition:   Lymphoma
    Interventions:   Drug: Rituximab;   Radiation: Radiation
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Non-Hodgkin's B-cell Lymphoma;   Leukemia, Lymphocytic, Chronic, B-Cell;   Small Lymphocytic Leukemia;   Diffuse Large B Cell Lymphoma;   Blood Cancer;   Hematological Malignancy
    Interventions:   Drug: MT-3724 Phase 1;   Drug: MT-3724 Phase 2
    Sponsor:   Molecular Templates, Inc.
    Recruiting

  • Conditions:   Advanced Solid Tumors Cancer;   Hematologic Malignancies
    Interventions:   Drug: ABBV-621;   Drug: Venetoclax;   Drug: Bevacizumab;   Drug: FOLFIRI
    Sponsor:   AbbVie
    Recruiting

  • Condition:   Lymphoma, Non-Hodgkin;Hodgkin Disease
    Interventions:   Drug: R-CHOP/CHOPE or ABVD chemotherapy regimen;   Drug: R-CDOP/CDOPE or DBVD chemotherapy regimen
    Sponsor:   Shandong Provincial Hospital
    Recruiting

  • Condition:   Richter Syndrome
    Interventions:   Drug: Acalabrutinib;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisolone;   Drug: Rituximab
    Sponsors:   University of Birmingham;   Bloodwise;   Acerta Pharma, LLC
    Not yet recruiting

  • Conditions:   Hodgkin's Lymphoma;   Lymphoma, Non-Hodgkin
    Interventions:   Drug: Bortezomib;   Drug: Ruxolitinib
    Sponsor:   University of Michigan Rogel Cancer Center
    Recruiting

  • Conditions:   Lymphoma, B-Cell;   Small Lymphocytic Lymphoma;   Chronic Lymphocytic Leukemia;   Waldenstrom Macroglobulinemia;   Mantle Cell Lymphoma;   Diffuse Large B Cell Lymphoma;   Richter's Transformation;   Follicular Lymphoma;   Marginal Zone Lymphoma
    Intervention:   Drug: ARQ 531
    Sponsor:   ArQule
    Recruiting

  • Conditions:   Hodgkin Disease;   Lymphoma, Non-hodgkin
    Interventions:   Drug: Carfilzomib;   Drug: TGR-1202
    Sponsor:   Changchun Deng
    Recruiting

  • Condition:   Lymphomas Non-Hodgkin's B-Cell
    Intervention:   Drug: Avelumab
    Sponsors:   Austin Health;   Merck KGaA, Darmstadt, Germany
    Recruiting

  • Conditions:   Lymphoma, Non-Hodgkin;   Lymphoma, Hodgkin
    Intervention:   Drug: Chemotherapy
    Sponsors:   Samsung Medical Center;   Samsung Genomic Institute
    Recruiting

  • Conditions:   Lymphoma, Non-Hodgkin;   Central Nervous System Neoplasms
    Interventions:   Diagnostic Test: 18F-FDG;   Diagnostic Test: 18F-fluciclovine;   Diagnostic Test: standard MRI
    Sponsors:   Norwegian University of Science and Technology;   St. Olavs Hospital
    Recruiting

  • Conditions:   Lymphoma, Non-Hodgkin;   Granulocyte Colony-Stimulating Factor;   Cost-Benefit Analysis
    Interventions:   Drug: PEG-rhG-CSF;   Drug: rhG-CSF
    Sponsor:   Ruijin Hospital
    Recruiting

  • Conditions:   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm
    Interventions:   Drug: busulfan;   Drug: cyclophosphamide;   Biological: Stem cell infusion;   Radiation: Total body irradiation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Lymphoma;   Lymphoma, Non-Hodgkin;   Large B Cell Diffuse Lymphoma
    Interventions:   Diagnostic Test: FLT-PET/CT;   Diagnostic Test: FDG-PET/CT;   Drug: FLT
    Sponsors:   Jonsson Comprehensive Cancer Center;   National Institutes of Health (NIH)
    Not yet recruiting

  • Conditions:   Rituximab;   Lymphoma, Non-Hodgkin;   Pediatric Cancer
    Intervention:  
    Sponsor:   Sun Yat-sen University
    Recruiting

  • Conditions:   Primary Sjögren Syndrome;   Lymphoma, Non-Hodgkin
    Intervention:   Procedure: Biopsy Salivary Gland
    Sponsor:   National Council of Scientific and Technical Research, Argentina
    Not yet recruiting

  • Condition:   Malignant Lymphoma
    Intervention:   Drug: Thiotepa
    Sponsor:   Sheba Medical Center
    Recruiting

  • Conditions:   CLL/SLL;   Lymphomas Non-Hodgkin's B-Cell
    Intervention:   Other: Long-Term Follow-Up of Patients who Received CAR-20/19-T cells
    Sponsor:   Medical College of Wisconsin
    Recruiting

  • Condition:   B-cell Lymphoma
    Intervention:   Drug: AC0010MA
    Sponsor:   Hangzhou ACEA Pharmaceutical Research Co., Ltd.
    Recruiting

  • Conditions:   Lymphoid Leukemia;   Small Lymphocytic Lymphoma;   Lymphoma, Non-Hodgkin
    Interventions:   Drug: Bendamustine;   Drug: Rituximab;   Drug: Lenalidomide
    Sponsors:   University of Wisconsin, Madison;   Celgene Corporation;   Genentech, Inc.
    Recruiting

  • Conditions:   Lymphoma, Non-Hodgkin;   Multiple Myeloma;   Advanced Solid Tumors
    Interventions:   Drug: Olaparib;   Drug: Dasatinib;   Drug: Nivolumab plus Ipilimumab;   Drug: Axitinib;   Drug: Bosutinib;   Drug: Crizotinib;   Drug: Palbociclib;   Drug: Sunitinib;   Drug: Temsirolimus;   Drug: Erlotinib;   Drug: Trastuzumab plus Pertuzumab;   Drug: Vemurafenib plus Cobimetinib;   Drug: Vismodegib
    Sponsors:   Canadian Cancer Trials Group;   AstraZeneca;   Bristol-Myers Squibb;   Hoffmann-La Roche;   Pfizer
    Recruiting

  • Conditions:   Lymphoma, Non-Hodgkin;   Multiple Myeloma;   Advanced Solid Tumors
    Interventions:   Drug: Crizotinib;   Drug: Palbociclib;   Drug: Sunitinib;   Drug: Temsirolimus;   Drug: Trastuzumab and Pertuzumab;   Drug: Vemurafenib and Cobimetinib;   Drug: Regorafenib;   Drug: Olaparib;   Drug: Pembrolizumab;   Drug: Nivolumab and Ipilimumab;   Drug: Abemaciclib;   Drug: Afatinib;   Drug: Talazoparib
    Sponsors:   American Society of Clinical Oncology;   AstraZeneca;   Bayer;   Bristol-Myers Squibb;   Eli Lilly and Company;   Genentech, Inc.;   Merck Sharp & Dohme Corp.;   Pfizer;   Boehringer Ingelheim
    Recruiting

  • Conditions:   MRD;   MDD;   Lymphoma, Nonhodgkin;   Anaplastic Lymphoma;   Pediatric Cancer
    Intervention:  
    Sponsor:   Sun Yat-sen University
    Recruiting

  • Conditions:   Lymphomas Non-Hodgkin's B-Cell;   Diffuse Large B-cell Lymphoma (DLBCL);   Primary Mediastinal B-cell Lymphoma (PMBCL);   Transformed Follicular Lymphoma (TFL);   Follicular Lymphoma (FL);   Mantle Cell Lymphoma (MCL)
    Interventions:   Biological: WZTL002-1 (1928T2z CAR-T cells);   Drug: Cyclophosphamide and Fludarabine lymphodepleting chemotherapy
    Sponsors:   Malaghan Institute of Medical Research;   Wellington Zhaotai Therapies Limited
    Not yet recruiting

  • Conditions:   Hodgkin Disease;   Lymphoma, Non-Hodgkin;   Lymphoma, B-Cell
    Interventions:   Biological: pembrolizumab;   Biological: MK-4280
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting

  • Conditions:   Lymphoma, Non-Hodgkin;   Lymphoblastic Lymphoma, Childhood;   PTEN Loss;   NOTCH1 Gene Mutation;   Pediatric Cancer
    Intervention:  
    Sponsor:   Sun Yat-sen University
    Recruiting

  • Condition:   Anaplastic Large-cell Lymphoma
    Intervention:   Drug: brentuximab vedotin
    Sponsor:   Millennium Pharmaceuticals, Inc.
    Recruiting

  • Conditions:   Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin;   Lymphoma, T-Cell, Cutaneous
    Intervention:   Drug: brentuximab vedotin
    Sponsors:   Seattle Genetics, Inc.;   Millennium Pharmaceuticals, Inc.
    Available

  • Conditions:   Lymphoma, Non-Hodgkin;   Lymphoma, Nonhodgkin;   Lymphoma, B-Cell;   Lymphoma, Large B-Cell, Diffuse
    Intervention:   Biological: lisocabtagene maraleucel
    Sponsors:   Juno Therapeutics, Inc.;   Celgene Corporation
    Recruiting